|
SANGER: Inhibition of human VA-ES-BJ cell growth in a cell viability assay.
|
Homo sapiens
|
5.256
nM
|
|
|
Antiproliferative activity against human MDA-MB-231 cells by MTT assay
|
Homo sapiens
|
11.4
nM
|
|
|
SANGER: Inhibition of human MDA-MB-231 cell growth in a cell viability assay.
|
Homo sapiens
|
27.78
nM
|
|
|
SANGER: Inhibition of human RERF-LC-MS cell growth in a cell viability assay.
|
Homo sapiens
|
176.69
nM
|
|
|
SANGER: Inhibition of human MHH-ES-1 cell growth in a cell viability assay.
|
Homo sapiens
|
0.05311
nM
|
|
|
SANGER: Inhibition of human C-33-A cell growth in a cell viability assay.
|
Homo sapiens
|
0.2733
nM
|
|
|
Antiproliferative activity against human A2780 cells expressing p53 gene after 72 hrs by proliferative assay
|
Homo sapiens
|
16.6
nM
|
|
|
Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
|
Homo sapiens
|
260.0
nM
|
|
|
SANGER: Inhibition of human LC4-1 cell growth in a cell viability assay.
|
Homo sapiens
|
74.74
nM
|
|
|
SANGER: Inhibition of human T84 cell growth in a cell viability assay.
|
Homo sapiens
|
15.96
nM
|
|
|
SANGER: Inhibition of human OVCAR-4 cell growth in a cell viability assay.
|
Homo sapiens
|
625.23
nM
|
|
|
SANGER: Inhibition of human NEC8 cell growth in a cell viability assay.
|
Homo sapiens
|
35.37
nM
|
|
|
SANGER: Inhibition of human MOLT-16 cell growth in a cell viability assay.
|
Homo sapiens
|
43.05
nM
|
|
|
SANGER: Inhibition of human ES4 cell growth in a cell viability assay.
|
Homo sapiens
|
0.0006531
nM
|
|
|
Antiproliferative activity against human p53 deficient Jurkat cells after 72 hrs by celltiter-glo assay
|
Homo sapiens
|
30.0
nM
|
|
|
Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
|
Homo sapiens
|
50.0
nM
|
|
|
Cytostatic activity against human MCF7 cells after 2 days by coulter counter analysis
|
Homo sapiens
|
7.2
nM
|
|
|
Antiproliferative activity against human PC-3 cells measured after 72 hrs by MTT assay
|
Homo sapiens
|
546.0
nM
|
|
|
SANGER: Inhibition of human IA-LM cell growth in a cell viability assay.
|
Homo sapiens
|
5.906
nM
|
|
|
SANGER: Inhibition of human DoTc2-4510 cell growth in a cell viability assay.
|
Homo sapiens
|
0.9012
nM
|
|
|
SANGER: Inhibition of human RPMI-7951 cell growth in a cell viability assay.
|
Homo sapiens
|
0.05413
nM
|
|
|
Inhibitory activity against SCC-25 (human, squamous cell carcinoma, tongue) cell line
|
Homo sapiens
|
47.0
nM
|
|
|
SANGER: Inhibition of human SCC-4 cell growth in a cell viability assay.
|
Homo sapiens
|
211.85
nM
|
|
|
Antitumor activity against human MIAPaCa2 cells xenografted mouse assessed as tumor growth inhibition at 200 mg/kg, ip administered weekly once for 3 weeks
|
Homo sapiens
|
82.0
%
|
|
|
Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
|
Homo sapiens
|
150.0
nM
|
|
|
SANGER: Inhibition of human EW-1 cell growth in a cell viability assay.
|
Homo sapiens
|
2.223
nM
|
|
|
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of Caco-2 cells at 10 uM after 48 hours by high content imaging
|
Homo sapiens
|
101.43
%
|
|
|
SANGER: Inhibition of human MRK-nu-1 cell growth in a cell viability assay.
|
Homo sapiens
|
2.567
nM
|
|
|
SANGER: Inhibition of human KE-37 cell growth in a cell viability assay.
|
Homo sapiens
|
0.005611
nM
|
|
|
Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay
|
Homo sapiens
|
25.0
nM
|
|
|
Cytotoxicity against human ACHN cells after 48 hrs by WST-8 assay
|
Homo sapiens
|
480.0
nM
|
|
|
SANGER: Inhibition of human NCI-H719 cell growth in a cell viability assay.
|
Homo sapiens
|
891.57
nM
|
|
|
Cytotoxicity against rat C6 cells after 3 days by MTT assay
|
Rattus norvegicus
|
504.0
nM
|
|
|
SANGER: Inhibition of human LCLC-97TM1 cell growth in a cell viability assay.
|
Homo sapiens
|
0.2673
nM
|
|
|
SANGER: Inhibition of human NCCIT cell growth in a cell viability assay.
|
Homo sapiens
|
176.26
nM
|
|
|
SANGER: Inhibition of human SCC-15 cell growth in a cell viability assay.
|
Homo sapiens
|
121.13
nM
|
|
|
Antiproliferative activity against human p53 deficient OVCAR8 cells after 72 hrs by celltiter-glo assay
|
Homo sapiens
|
3.0
nM
|
|
|
SANGER: Inhibition of human KYSE-270 cell growth in a cell viability assay.
|
Homo sapiens
|
0.6341
nM
|
|
|
SANGER: Inhibition of human HCE-4 cell growth in a cell viability assay.
|
Homo sapiens
|
0.05283
nM
|
|
|
SANGER: Inhibition of human NB13 cell growth in a cell viability assay.
|
Homo sapiens
|
38.23
nM
|
|
|
SANGER: Inhibition of human CAL-62 cell growth in a cell viability assay.
|
Homo sapiens
|
1.215
nM
|
|
|
SANGER: Inhibition of human OAW-42 cell growth in a cell viability assay.
|
Homo sapiens
|
92.14
nM
|
|
|
SANGER: Inhibition of human MC116 cell growth in a cell viability assay.
|
Homo sapiens
|
481.66
nM
|
|
|
SANGER: Inhibition of human AU565 cell growth in a cell viability assay.
|
Homo sapiens
|
21.83
nM
|
|
|
SANGER: Inhibition of human SK-OV-3 cell growth in a cell viability assay.
|
Homo sapiens
|
38.74
nM
|
|
|
SANGER: Inhibition of human DU-145 cell growth in a cell viability assay.
|
Homo sapiens
|
9.29
nM
|
|
|
Inhibitory activity against HeLa (human, epitheloid carcinoma, cervix) cell line
|
Homo sapiens
|
8.0
nM
|
|
|
Anticancer activity against human SMMC-7721 cells assessed as inhibition of cell proliferation at 10 uM measured after 72 hrs by MTT assay
|
Homo sapiens
|
61.5
%
|
|
|
SANGER: Inhibition of human MLMA cell growth in a cell viability assay.
|
Homo sapiens
|
271.56
nM
|
|
|
SANGER: Inhibition of human HT-29 cell growth in a cell viability assay.
|
Homo sapiens
|
0.04128
nM
|
|
|
SANGER: Inhibition of human OCUB-M cell growth in a cell viability assay.
|
Homo sapiens
|
10.03
nM
|
|
|
SANGER: Inhibition of human HuP-T4 cell growth in a cell viability assay.
|
Homo sapiens
|
27.3
nM
|
|
|
SANGER: Inhibition of human L-428 cell growth in a cell viability assay.
|
Homo sapiens
|
23.62
nM
|
|
|
SANGER: Inhibition of human SK-UT-1 cell growth in a cell viability assay.
|
Homo sapiens
|
0.02969
nM
|
|
|
Cytotoxicity against mrp-1/mdr-1 overexpressing human CEM-DNR-bulk cells assessed as cell growth inhibition after 72 hrs by MTS assay
|
Homo sapiens
|
100.0
nM
|
|
|
SANGER: Inhibition of human 647-V cell growth in a cell viability assay.
|
Homo sapiens
|
0.2481
nM
|
|
|
Inhibitory activity against BxPC3 (human,pancreas,adenocarcinoma) cell line
|
Homo sapiens
|
160.0
nM
|
|
|
SANGER: Inhibition of human HEC-1 cell growth in a cell viability assay.
|
Homo sapiens
|
123.63
nM
|
|
|
SANGER: Inhibition of human IGR-1 cell growth in a cell viability assay.
|
Homo sapiens
|
14.42
nM
|
|
|
Antiviral activity against Human cytomegalovirus Davis infected in human HEL cells assessed as reduction in virus plaque formation measured on 6 to 7 post-viral infection
|
Human betaherpesvirus 5
|
53.0
nM
|
|
|
SANGER: Inhibition of human NCI-H209 cell growth in a cell viability assay.
|
Homo sapiens
|
52.07
nM
|
|
|
SANGER: Inhibition of human G-402 cell growth in a cell viability assay.
|
Homo sapiens
|
0.7844
nM
|
|
|
Antiproliferative activity against p53 deficient human Jurkat cells after 72 hrs by proliferative assay
|
Homo sapiens
|
45.3
nM
|
|
|
Cytotoxicity against human BXPC-3 cells assessed as inhibition of cell growth measured after 72 hrs by SRB assay
|
Homo sapiens
|
130.0
nM
|
|
|
SANGER: Inhibition of human Daudi cell growth in a cell viability assay.
|
Homo sapiens
|
569.49
nM
|
|
|
SANGER: Inhibition of human 639-V cell growth in a cell viability assay.
|
Homo sapiens
|
193.14
nM
|
|
|
SANGER: Inhibition of human SW1463 cell growth in a cell viability assay.
|
Homo sapiens
|
510.17
nM
|
|
|
Antiproliferative activity against human CEM-DNR-bulk cells after 3 days by MTS assay
|
Homo sapiens
|
100.0
nM
|
|
|
SANGER: Inhibition of human EW-7 cell growth in a cell viability assay.
|
Homo sapiens
|
0.002578
nM
|
|
|
Inhibition of DNA synthesis in chemoresistant human MIAPaCa2 cells assessed as incorporation of [3H]thymidine into DNA after 4 hrs by liquid scintillation counting
|
Homo sapiens
|
90.0
%
|
|
|
SANGER: Inhibition of human SK-HEP-1 cell growth in a cell viability assay.
|
Homo sapiens
|
6.136
nM
|
|
|
Antiproliferative activity against human SF539 cells expressing p53 gene after 72 hrs by proliferative assay
|
Homo sapiens
|
19.8
nM
|
|
|
SANGER: Inhibition of human U031 cell growth in a cell viability assay.
|
Homo sapiens
|
0.5647
nM
|
|
|
Cytotoxicity against human HeLa cells after 72 hrs by resazurin assay
|
Homo sapiens
|
50.0
nM
|
|
|
Cytotoxicity against human HPAC cells after 3 days by MTT assay
|
Homo sapiens
|
73.0
nM
|
|
|
SANGER: Inhibition of human TE-5 cell growth in a cell viability assay.
|
Homo sapiens
|
0.3157
nM
|
|
|
SANGER: Inhibition of human YKG-1 cell growth in a cell viability assay.
|
Homo sapiens
|
0.4194
nM
|
|
|
SANGER: Inhibition of human QIMR-WIL cell growth in a cell viability assay.
|
Homo sapiens
|
0.008942
nM
|
|
|
SANGER: Inhibition of human AGS cell growth in a cell viability assay.
|
Homo sapiens
|
0.09016
nM
|
|
|
SANGER: Inhibition of human EW-3 cell growth in a cell viability assay.
|
Homo sapiens
|
579.56
nM
|
|
|
SANGER: Inhibition of human LCLC-103H cell growth in a cell viability assay.
|
Homo sapiens
|
33.25
nM
|
|
|
SANGER: Inhibition of human EW-13 cell growth in a cell viability assay.
|
Homo sapiens
|
0.01122
nM
|
|
|
SANGER: Inhibition of human COLO-684 cell growth in a cell viability assay.
|
Homo sapiens
|
26.41
nM
|
|
|
SANGER: Inhibition of human NCI-H838 cell growth in a cell viability assay.
|
Homo sapiens
|
498.75
nM
|
|
|
SANGER: Inhibition of human NALM-6 cell growth in a cell viability assay.
|
Homo sapiens
|
0.06223
nM
|
|
|
Growth inhibition of A2780 cells by SRB assay
|
Homo sapiens
|
1.5
nM
|
|
|
Cytotoxicity against human HCT116 cells after 48 hrs by WST-8 assay
|
Homo sapiens
|
320.0
nM
|
|
|
Antiproliferative activity against human HCT116 cells expressing p53 after 72 hrs by celltiter-glo assay
|
Homo sapiens
|
6.0
nM
|
|
|
SANGER: Inhibition of human EFO-21 cell growth in a cell viability assay.
|
Homo sapiens
|
53.66
nM
|
|
|
SANGER: Inhibition of human CAL-12T cell growth in a cell viability assay.
|
Homo sapiens
|
1.084
nM
|
|
|
Antiproliferative activity against human DU145 cells measured after 72 hrs by MTT assay
|
Homo sapiens
|
213.0
nM
|
|
|
Antiviral activity against HIV1 infected in human U373-MAGI cells incubated for 2 hrs prior to viral infection followed by compound washout after 24 hrs measured 72 hrs post-infection by flow cytometry
|
Human immunodeficiency virus 1
|
27.5
nM
|
|
|
Cytotoxicity against human CEM-DNR-bulk cells after 3 days by MTT assay
|
Homo sapiens
|
22.0
nM
|
|
|
SANGER: Inhibition of human J82 cell growth in a cell viability assay.
|
Homo sapiens
|
7.41
nM
|
|
|
SANGER: Inhibition of human COR-L105 cell growth in a cell viability assay.
|
Homo sapiens
|
29.42
nM
|
|
|
Antiviral activity against Hepatitis C virus assessed as inhibition of viral replication incubated for 3 days by Renilla luciferase based assay
|
Hepatitis C virus
|
12.0
nM
|
|
|
SANGER: Inhibition of human HuP-T3 cell growth in a cell viability assay.
|
Homo sapiens
|
145.65
nM
|
|
|
SANGER: Inhibition of human SNU-387 cell growth in a cell viability assay.
|
Homo sapiens
|
827.44
nM
|
|
|
Cytotoxicity against human K562 cells after 3 days by MTT assay
|
Homo sapiens
|
718.0
nM
|
|
|
Cytotoxicity against human T24 cells treated at LA + compound sequent. compound for 24 hrs, LA + compound for 24 hrs additional, total 48 hrs 2:1 and 5:1 alpha-lipoic acid to compound ratio after 48 hrs by SRB assay in presence of alpha-lipoic acid
|
Homo sapiens
|
3.9
nM
|
|
|
SANGER: Inhibition of human MC-CAR cell growth in a cell viability assay.
|
Homo sapiens
|
11.58
nM
|
|
|
Cytotoxicity against human PANC-1 cells assessed as reduction in cell viability measured after 72 hrs by SRB assay
|
Homo sapiens
|
22.0
nM
|
|
|
Antiproliferative activity against human K562 cells after 48 hrs by MTT assay
|
Homo sapiens
|
110.0
nM
|
|
|
SANGER: Inhibition of human KARPAS-299 cell growth in a cell viability assay.
|
Homo sapiens
|
252.0
nM
|
|
|
Cytotoxicity against HPDEC assessed as decrease in cell proliferation after 72 hrs by MTT assay
|
Homo sapiens
|
140.0
nM
|
|
|
Growth inhibition of H460 cells by SRB assay in presence of dipyridamole
|
Homo sapiens
|
103.0
nM
|
|
|
Cytotoxicity against human A549 cells treated at LA + compound sequent. compound for 24 hrs, LA + compound for 24 hrs additional, total 48 hrs 2:1 and 5:1 alpha-lipoic acid to compound ratio after 48 hrs by SRB assay in presence of alpha-lipoic acid
|
Homo sapiens
|
3.9
nM
|
|
|
SANGER: Inhibition of human NCI-H1693 cell growth in a cell viability assay.
|
Homo sapiens
|
46.09
nM
|
|
|
SANGER: Inhibition of human TGW cell growth in a cell viability assay.
|
Homo sapiens
|
199.64
nM
|
|
|
Antiproliferative activity against human PC3 cells measured after 72 hrs by MTT assay
|
Homo sapiens
|
416.0
nM
|
|
|
SANGER: Inhibition of human ES3 cell growth in a cell viability assay.
|
Homo sapiens
|
44.6
nM
|
|
|
SANGER: Inhibition of human PSN1 cell growth in a cell viability assay.
|
Homo sapiens
|
0.01652
nM
|
|
|
SANGER: Inhibition of human SW626 cell growth in a cell viability assay.
|
Homo sapiens
|
4.464
nM
|
|
|
SANGER: Inhibition of human OE33 cell growth in a cell viability assay.
|
Homo sapiens
|
61.17
nM
|
|
|
Growth inhibition of A549 cells by SRB assay
|
Homo sapiens
|
14.0
nM
|
|
|
Cytotoxicity against human PC-3 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay
|
Homo sapiens
|
74.0
nM
|
|
|
SANGER: Inhibition of human NCI-H292 cell growth in a cell viability assay.
|
Homo sapiens
|
20.79
nM
|
|
|
Antiproliferative activity against p53 deficient human A2780/E6 cells after 72 hrs by proliferative assay
|
Homo sapiens
|
2.6
nM
|
|
|
SANGER: Inhibition of human OAW-28 cell growth in a cell viability assay.
|
Homo sapiens
|
45.36
nM
|
|
|
SANGER: Inhibition of human CAL-85-1 cell growth in a cell viability assay.
|
Homo sapiens
|
144.63
nM
|
|
|
Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) expressing NS116-GFP infected in human RPE cells assessed as inhibition of viral replication measured after 24 hrs by luminescence based assay
|
Influenza A virus
|
68.0
nM
|
|
|
SANGER: Inhibition of human CAL-54 cell growth in a cell viability assay.
|
Homo sapiens
|
297.59
nM
|
|
|
Antiviral activity against SARS-CoV-2 UC-1074 infected in African green monkey Vero cells assessed as reduction in virus plaque formation measured on day 5 post-viral infection by microscopic analysis
|
Severe acute respiratory syndrome coronavirus 2
|
3.2
nM
|
|
|
SANGER: Inhibition of human SH-4 cell growth in a cell viability assay.
|
Homo sapiens
|
9.022
nM
|
|
|
SANGER: Inhibition of human SNU-449 cell growth in a cell viability assay.
|
Homo sapiens
|
13.77
nM
|
|
|
SANGER: Inhibition of human ES7 cell growth in a cell viability assay.
|
Homo sapiens
|
19.76
nM
|
|
|
Cytotoxicity against human MRC5 cells treated at LA + compound sequent. compound for 24 hrs, LA + compound for 24 hrs additional, total 48 hrs 2:1 and 5:1 alpha-lipoic acid to compound ratio after 48 hrs by SRB assay in presence of alpha-lipoic acid
|
Homo sapiens
|
3.9
nM
|
|
|
SANGER: Inhibition of human TYK-nu cell growth in a cell viability assay.
|
Homo sapiens
|
72.64
nM
|
|
|
SANGER: Inhibition of human KMOE-2 cell growth in a cell viability assay.
|
Homo sapiens
|
154.93
nM
|
|
|
SANGER: Inhibition of human A2058 cell growth in a cell viability assay.
|
Homo sapiens
|
32.83
nM
|
|
|
In vitro cytotoxic activity against colon adenocarcinoma (HT-29) cells assayed by inhibition of [3H]-labeled thymidine incorporation
|
Homo sapiens
|
3.0
nM
|
|
|
SANGER: Inhibition of human OE19 cell growth in a cell viability assay.
|
Homo sapiens
|
702.16
nM
|
|
|
SANGER: Inhibition of human IPC-298 cell growth in a cell viability assay.
|
Homo sapiens
|
254.77
nM
|
|
|
SANGER: Inhibition of human NCI-H358 cell growth in a cell viability assay.
|
Homo sapiens
|
7.16
nM
|
|
|
SANGER: Inhibition of human MZ2-MEL cell growth in a cell viability assay.
|
Homo sapiens
|
26.22
nM
|
|
|
SANGER: Inhibition of human CHL-1 cell growth in a cell viability assay.
|
Homo sapiens
|
0.03241
nM
|
|
|
SANGER: Inhibition of human BL-41 cell growth in a cell viability assay.
|
Homo sapiens
|
14.37
nM
|
|
|
SANGER: Inhibition of human NCI-H1755 cell growth in a cell viability assay.
|
Homo sapiens
|
718.16
nM
|
|
|
Cytotoxicity against human T24 cells treated at LA + compound sequent. LA for 24 hrs), LA + GEM (24 hrs additional, total 48 hrs) 5:1 alpha-lipoic acid to compound ratio after 48 hrs by SRB assay in presence of alpha-lipoic acid
|
Homo sapiens
|
17.0
nM
|
|
|
SANGER: Inhibition of human no-10 cell growth in a cell viability assay.
|
Homo sapiens
|
173.76
nM
|
|
|
SANGER: Inhibition of human HUTU-80 cell growth in a cell viability assay.
|
Homo sapiens
|
0.01664
nM
|
|
|
Cytotoxicity against human PC3 cells by sulforhodamine B method
|
Homo sapiens
|
40.0
nM
|
|
|
SANGER: Inhibition of human NCI-H2170 cell growth in a cell viability assay.
|
Homo sapiens
|
11.97
nM
|
|
|
SANGER: Inhibition of human Ca-Ski cell growth in a cell viability assay.
|
Homo sapiens
|
7.093
nM
|
|
|
Cytotoxicity against human MIAPaCa2 cells after 72 hrs by resazurin assay
|
Homo sapiens
|
60.0
nM
|
|
|
SANGER: Inhibition of human NCI-H23 cell growth in a cell viability assay.
|
Homo sapiens
|
211.06
nM
|
|
|
SANGER: Inhibition of human CHP-126 cell growth in a cell viability assay.
|
Homo sapiens
|
24.14
nM
|
|
|
Cytotoxicity against human MIAPaCa2 cells incubated for 24 hrs by MTT assay
|
Homo sapiens
|
16.0
nM
|
|
|
SANGER: Inhibition of human CaR-1 cell growth in a cell viability assay.
|
Homo sapiens
|
551.22
nM
|
|
|
SANGER: Inhibition of human GT3TKB cell growth in a cell viability assay.
|
Homo sapiens
|
42.72
nM
|
|
|
Cytostatic activity against human A549 cells after 3 days by MTS assay
|
Homo sapiens
|
50.0
nM
|
|
|
SANGER: Inhibition of human DOHH-2 cell growth in a cell viability assay.
|
Homo sapiens
|
195.64
nM
|
|
|
Cytotoxicity against human MRC5 cells treated at LA + compound sequent. LA for 24 hrs), LA + GEM (24 hrs additional, total 48 hrs) 5:1 alpha-lipoic acid to compound ratio after 48 hrs by SRB assay in presence of alpha-lipoic acid
|
Homo sapiens
|
6.8
nM
|
|
|
SANGER: Inhibition of human K5 cell growth in a cell viability assay.
|
Homo sapiens
|
682.69
nM
|
|
|
SANGER: Inhibition of human NCI-H2009 cell growth in a cell viability assay.
|
Homo sapiens
|
0.6187
nM
|
|
|
Cytotoxicity against human A549 cells assessed as cell growth inhibition after 72 hrs by MTS assay
|
Homo sapiens
|
50.0
nM
|
|
|
SANGER: Inhibition of human C-4-II cell growth in a cell viability assay.
|
Homo sapiens
|
152.37
nM
|
|
|
Antiproliferative activity against human p53 deficient K562 cells after 72 hrs by celltiter-glo assay
|
Homo sapiens
|
600.0
nM
|
|
|
SANGER: Inhibition of human TE-15 cell growth in a cell viability assay.
|
Homo sapiens
|
0.04637
nM
|
|
|
SANGER: Inhibition of human A4-Fuk cell growth in a cell viability assay.
|
Homo sapiens
|
0.6263
nM
|
|
|
Growth inhibition of human Capan1 cells after 96 hrs by SRB assay
|
Homo sapiens
|
19.0
nM
|
|
|
Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay
|
Homo sapiens
|
520.0
nM
|
|
|
SANGER: Inhibition of human MDA-MB-468 cell growth in a cell viability assay.
|
Homo sapiens
|
14.12
nM
|
|
|
SANGER: Inhibition of human HCT-116 cell growth in a cell viability assay.
|
Homo sapiens
|
50.83
nM
|
|
|
SANGER: Inhibition of human TE-9 cell growth in a cell viability assay.
|
Homo sapiens
|
189.63
nM
|
|
|
SANGER: Inhibition of human HEL cell growth in a cell viability assay.
|
Homo sapiens
|
1.791
nM
|
|
|
SANGER: Inhibition of human SF126 cell growth in a cell viability assay.
|
Homo sapiens
|
7.054
nM
|
|
|
Substrate activity at ENT1 in human BXPC-3 cells assessed as inhibition of cell growth pretreated with ENT1 inhibitor nitrobenzylthioinosine for 5 mins measured after 72 hrs by SRB assay
|
Homo sapiens
|
190.0
nM
|
|
|
SANGER: Inhibition of human NCI-SNU-5 cell growth in a cell viability assay.
|
Homo sapiens
|
12.13
nM
|
|
|
Cytotoxicity against human A549 cells treated at 2:1 and 5:1 alpha-lipoic acid to compound ratio after 48 hrs by SRB assay in presence of alpha-lipoic acid
|
Homo sapiens
|
3.9
nM
|
|
|
SANGER: Inhibition of human EW-11 cell growth in a cell viability assay.
|
Homo sapiens
|
433.52
nM
|
|
|
Antiproliferative activity against human MIAPaCa2 cells after 70 hrs by alamar blue assay
|
Homo sapiens
|
120.0
nM
|
|
|
SANGER: Inhibition of human EW-16 cell growth in a cell viability assay.
|
Homo sapiens
|
0.02299
nM
|
|
|
Growth inhibition of H460 cells by SRB assay
|
Homo sapiens
|
10.0
nM
|
|
|
SANGER: Inhibition of human KYSE-140 cell growth in a cell viability assay.
|
Homo sapiens
|
27.91
nM
|
|
|
SANGER: Inhibition of human DSH1 cell growth in a cell viability assay.
|
Homo sapiens
|
96.5
nM
|
|
|
Cytotoxicity against human A549 cells after 48 hrs by SRB assay
|
Homo sapiens
|
6.8
nM
|
|
|
Inhibition of chemoresistant human MIAPaCa2 cell proliferation after 48 hrs by MTT assay
|
Homo sapiens
|
30.0
%
|
|
|
SANGER: Inhibition of human 786-0 cell growth in a cell viability assay.
|
Homo sapiens
|
0.023
nM
|
|
|
Antiproliferative activity against human p53 deficient PC3 cells after 72 hrs by celltiter-glo assay
|
Homo sapiens
|
3.0
nM
|
|
|
SANGER: Inhibition of human CAPAN-1 cell growth in a cell viability assay.
|
Homo sapiens
|
9.227
nM
|
|
|
SANGER: Inhibition of human PA-1 cell growth in a cell viability assay.
|
Homo sapiens
|
8.993
nM
|
|
|
SANGER: Inhibition of human COLO-320-HSR cell growth in a cell viability assay.
|
Homo sapiens
|
224.08
nM
|
|
|
SANGER: Inhibition of human GP5d cell growth in a cell viability assay.
|
Homo sapiens
|
28.72
nM
|
|
|
SANGER: Inhibition of human RPMI-8866 cell growth in a cell viability assay.
|
Homo sapiens
|
95.23
nM
|
|
|
SANGER: Inhibition of human SW1783 cell growth in a cell viability assay.
|
Homo sapiens
|
0.03355
nM
|
|
|
SANGER: Inhibition of human DJM-1 cell growth in a cell viability assay.
|
Homo sapiens
|
21.59
nM
|
|
|
Cytostatic activity against mouse L1210 cells after 48 hrs by coulter counter analysis
|
Mus musculus
|
13.0
nM
|
|
|
SANGER: Inhibition of human HCC1569 cell growth in a cell viability assay.
|
Homo sapiens
|
109.36
nM
|
|
|
SANGER: Inhibition of human LU-139 cell growth in a cell viability assay.
|
Homo sapiens
|
14.59
nM
|
|
|
SANGER: Inhibition of human VM-CUB-1 cell growth in a cell viability assay.
|
Homo sapiens
|
34.69
nM
|
|
|
SANGER: Inhibition of human ME-180 cell growth in a cell viability assay.
|
Homo sapiens
|
38.8
nM
|
|
|
Antiproliferative activity against human PC3 cells expressing p53 gene after 72 hrs by proliferative assay
|
Homo sapiens
|
2.6
nM
|
|
|
SANGER: Inhibition of human CHP-212 cell growth in a cell viability assay.
|
Homo sapiens
|
2.752
nM
|
|
|
Cytostatic activity against human K562 cells after 3 days by MTS assay
|
Homo sapiens
|
100.0
nM
|
|
|
SANGER: Inhibition of human LoVo cell growth in a cell viability assay.
|
Homo sapiens
|
5.714
nM
|
|
|
SANGER: Inhibition of human SW982 cell growth in a cell viability assay.
|
Homo sapiens
|
0.2133
nM
|
|
|
SANGER: Inhibition of human IST-SL2 cell growth in a cell viability assay.
|
Homo sapiens
|
0.05844
nM
|
|
|
SANGER: Inhibition of human GAK cell growth in a cell viability assay.
|
Homo sapiens
|
372.94
nM
|
|
|
SANGER: Inhibition of human A253 cell growth in a cell viability assay.
|
Homo sapiens
|
102.28
nM
|
|
|
SANGER: Inhibition of human P12-ICHIKAWA cell growth in a cell viability assay.
|
Homo sapiens
|
84.7
nM
|
|
|
SANGER: Inhibition of human COR-L23 cell growth in a cell viability assay.
|
Homo sapiens
|
14.13
nM
|
|
|
Cytostatic activity against mouse L1210 cells after 2 days by coulter counter analysis
|
Mus musculus
|
13.0
nM
|
|
|
SANGER: Inhibition of human Becker cell growth in a cell viability assay.
|
Homo sapiens
|
267.04
nM
|
|
|
Cytotoxicity against human A549 cells by sulforhodamine B method
|
Homo sapiens
|
90.0
nM
|
|
|
Antiproliferative activity against human PDAC-3 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay
|
Homo sapiens
|
30.0
nM
|
|
|
Cytostatic activity against human HCT116 p53-/- cells after 3 days by MTS assay
|
Homo sapiens
|
410.0
nM
|
|
|
SANGER: Inhibition of human BCPAP cell growth in a cell viability assay.
|
Homo sapiens
|
1.452
nM
|
|
|
Cytotoxicity against human MDA-MB-231 cells after 24 hrs by MTT colorimetric assay
|
Homo sapiens
|
190.0
nM
|
|
|
Antitumor activity against human A549 cells xenografted in nu/nu mouse assessed as inhibition of tumor volume at 10 mg/kg, ip administered three times a week for 3 weeks
|
Homo sapiens
|
76.7
%
|
|
|
SANGER: Inhibition of human KM-H2 cell growth in a cell viability assay.
|
Homo sapiens
|
260.68
nM
|
|
|
SANGER: Inhibition of human RD cell growth in a cell viability assay.
|
Homo sapiens
|
130.11
nM
|
|
|
SANGER: Inhibition of human SW756 cell growth in a cell viability assay.
|
Homo sapiens
|
45.14
nM
|
|
|
Cytotoxicity against human U87 cells assessed as reduction in cell viability incubated for 72 hrs by AlamarBlue assay
|
Homo sapiens
|
8.2
nM
|
|
|
Cytotoxicity against human T24 cells treated at LA + compound sequent. LA for 24 hrs), LA + GEM (24 hrs additional, total 48 hrs) 2:1 alpha-lipoic acid to compound ratio after 48 hrs by SRB assay in presence of alpha-lipoic acid
|
Homo sapiens
|
18.0
nM
|
|
|
Antiproliferative activity against human CCRF-CEM cells after 3 days by MTS assay
|
Homo sapiens
|
20.0
nM
|
|
|
SANGER: Inhibition of human HCT-15 cell growth in a cell viability assay.
|
Homo sapiens
|
82.16
nM
|
|
|
SANGER: Inhibition of human SW1710 cell growth in a cell viability assay.
|
Homo sapiens
|
0.07513
nM
|
|
|
SANGER: Inhibition of human NCI-H2030 cell growth in a cell viability assay.
|
Homo sapiens
|
30.45
nM
|
|
|
SANGER: Inhibition of human CAL-51 cell growth in a cell viability assay.
|
Homo sapiens
|
191.14
nM
|
|
|
SANGER: Inhibition of human KALS-1 cell growth in a cell viability assay.
|
Homo sapiens
|
21.39
nM
|
|
|
SANGER: Inhibition of human HT-1080 cell growth in a cell viability assay.
|
Homo sapiens
|
5.834
nM
|
|
|
SANGER: Inhibition of human NCI-H1648 cell growth in a cell viability assay.
|
Homo sapiens
|
510.81
nM
|
|
|
SANGER: Inhibition of human NCI-H1155 cell growth in a cell viability assay.
|
Homo sapiens
|
488.28
nM
|
|
|
Antiproliferative activity against human K562-TAX cells after 3 days by MTS assay
|
Homo sapiens
|
50.0
nM
|
|
|
Cytostatic activity against human U2OS cells after 3 days by MTS assay
|
Homo sapiens
|
180.0
nM
|
|
|
SANGER: Inhibition of human AN3-CA cell growth in a cell viability assay.
|
Homo sapiens
|
203.29
nM
|
|
|
SANGER: Inhibition of human DEL cell growth in a cell viability assay.
|
Homo sapiens
|
0.08871
nM
|
|
|
SANGER: Inhibition of human ST486 cell growth in a cell viability assay.
|
Homo sapiens
|
9.406
nM
|
|
|
SANGER: Inhibition of human CESS cell growth in a cell viability assay.
|
Homo sapiens
|
23.19
nM
|
|
|
SANGER: Inhibition of human ES8 cell growth in a cell viability assay.
|
Homo sapiens
|
0.7802
nM
|
|
|
SANGER: Inhibition of human Raji cell growth in a cell viability assay.
|
Homo sapiens
|
431.45
nM
|
|
|
SANGER: Inhibition of human G-401 cell growth in a cell viability assay.
|
Homo sapiens
|
55.16
nM
|
|
|
SANGER: Inhibition of human 8505C cell growth in a cell viability assay.
|
Homo sapiens
|
1.063
nM
|
|
|
SANGER: Inhibition of human DB cell growth in a cell viability assay.
|
Homo sapiens
|
84.4
nM
|
|
|
Antiviral activity against HCV infected in human Huh-7 cells assessed as reduction in viral replication preincubated for 2 hrs followed by replacement with fresh culture medium and measured after 46 hrs by luciferase reporter gene assay
|
Hepatitis C virus
|
170.0
nM
|
|
|
SANGER: Inhibition of human FADU cell growth in a cell viability assay.
|
Homo sapiens
|
105.45
nM
|
|
|
SANGER: Inhibition of human MKN1 cell growth in a cell viability assay.
|
Homo sapiens
|
78.37
nM
|
|
|
Cytostatic activity against human CEM cells after 72 hrs by coulter counter analysis
|
Homo sapiens
|
86.0
nM
|
|
|
SANGER: Inhibition of human NCI-H520 cell growth in a cell viability assay.
|
Homo sapiens
|
18.77
nM
|
|
|
SANGER: Inhibition of human ACHN cell growth in a cell viability assay.
|
Homo sapiens
|
0.0008872
nM
|
|
|
Growth inhibition of human MDA-MB-231 cells at 0.2 uM after 96 hrs by sulforhodamine B assay relative to control
|
Homo sapiens
|
17.7
%
|
|
|
Antiproliferative activity against human HCT116 cells after 3 days by MTS assay
|
Homo sapiens
|
30.0
nM
|
|
|
SANGER: Inhibition of human KYSE-450 cell growth in a cell viability assay.
|
Homo sapiens
|
6.315
nM
|
|
|
SANGER: Inhibition of human M059J cell growth in a cell viability assay.
|
Homo sapiens
|
21.08
nM
|
|
|
SANGER: Inhibition of human L-540 cell growth in a cell viability assay.
|
Homo sapiens
|
1.602
nM
|
|
|
SANGER: Inhibition of human BFTC-909 cell growth in a cell viability assay.
|
Homo sapiens
|
145.6
nM
|
|
|
Antiviral activity against SARS-CoV-2 UC-1075 infected in African green monkey Vero cells assessed as reduction in virus plaque formation measured on day 5 post-viral infection by microscopic analysis
|
Severe acute respiratory syndrome coronavirus 2
|
1.6
nM
|
|
|
SANGER: Inhibition of human A375 cell growth in a cell viability assay.
|
Homo sapiens
|
0.009949
nM
|
|
|
Antiproliferative activity against human MIAPaCa2 cells after 2 days by MTT assay
|
Homo sapiens
|
29.0
%
|
|
|
SANGER: Inhibition of human NTERA-S-cl-D1 cell growth in a cell viability assay.
|
Homo sapiens
|
1.641
nM
|
|
|
Antiproliferative activity against human SF539 cells expressing p53 after 72 hrs by celltiter-glo assay
|
Homo sapiens
|
20.0
nM
|
|
|
SANGER: Inhibition of human SAS cell growth in a cell viability assay.
|
Homo sapiens
|
20.5
nM
|
|
|
Cytotoxicity against mouse B16F10 cells assessed as decrease in cell viability after 72 hrs by MTT assay
|
Mus musculus
|
260.0
nM
|
|
|
SANGER: Inhibition of human U-698-M cell growth in a cell viability assay.
|
Homo sapiens
|
344.53
nM
|
|
|
SANGER: Inhibition of human LB647-SCLC cell growth in a cell viability assay.
|
Homo sapiens
|
1.18
nM
|
|
|
SANGER: Inhibition of human SK-LMS-1 cell growth in a cell viability assay.
|
Homo sapiens
|
0.5776
nM
|
|
|
SANGER: Inhibition of human Ramos-2G6-4C10 cell growth in a cell viability assay.
|
Homo sapiens
|
660.87
nM
|
|
|
SANGER: Inhibition of human BOKU cell growth in a cell viability assay.
|
Homo sapiens
|
254.33
nM
|
|
|
SANGER: Inhibition of human TE-8 cell growth in a cell viability assay.
|
Homo sapiens
|
8.001
nM
|
|
|
In vitro cytotoxic activity against uterine sarcoma (MES-SA) cells assayed by inhibition of [3H]-labeled thymidine incorporation
|
Homo sapiens
|
9.2
nM
|
|
|
Antiviral activity against HCV infected in human Huh-7 cells assessed as reduction in viral replication measured after 48 hrs by luciferase reporter gene assay
|
Hepatitis C virus
|
58.0
nM
|
|
|
SANGER: Inhibition of human SJSA-1 cell growth in a cell viability assay.
|
Homo sapiens
|
195.01
nM
|
|
|
SANGER: Inhibition of human COLO-800 cell growth in a cell viability assay.
|
Homo sapiens
|
40.56
nM
|
|
|
SANGER: Inhibition of human SW837 cell growth in a cell viability assay.
|
Homo sapiens
|
27.62
nM
|
|
|
SANGER: Inhibition of human NCI-H2052 cell growth in a cell viability assay.
|
Homo sapiens
|
144.82
nM
|
|
|
Antiproliferative activity against human A549 cells after 3 days by MTS assay
|
Homo sapiens
|
50.0
nM
|
|
|
SANGER: Inhibition of human LB996-RCC cell growth in a cell viability assay.
|
Homo sapiens
|
65.09
nM
|
|
|
SANGER: Inhibition of human SK-CO-1 cell growth in a cell viability assay.
|
Homo sapiens
|
34.01
nM
|
|
|
SANGER: Inhibition of human D-283MED cell growth in a cell viability assay.
|
Homo sapiens
|
126.98
nM
|
|
|
SANGER: Inhibition of human BPH-1 cell growth in a cell viability assay.
|
Homo sapiens
|
20.28
nM
|
|
|
Cytotoxicity against human RT112 cells assessed as cell viability by MTT assay in presence of dCK substrate deoxycytidine
|
Homo sapiens
|
104.9
nM
|
|
|
SANGER: Inhibition of human SK-MES-1 cell growth in a cell viability assay.
|
Homo sapiens
|
0.3279
nM
|
|
|
SANGER: Inhibition of human LOXIMVI cell growth in a cell viability assay.
|
Homo sapiens
|
1.596
nM
|
|
|
SANGER: Inhibition of human LAMA-84 cell growth in a cell viability assay.
|
Homo sapiens
|
115.04
nM
|
|
|
SARS-CoV-2 3CL-Pro protease inhibition percentage at 20µM by FRET kind of response from peptide substrate
|
Severe acute respiratory syndrome coronavirus 2
|
20.53
%
|
|
|
SANGER: Inhibition of human SW954 cell growth in a cell viability assay.
|
Homo sapiens
|
23.68
nM
|
|
|
SANGER: Inhibition of human UM-UC-3 cell growth in a cell viability assay.
|
Homo sapiens
|
16.16
nM
|
|
|
SANGER: Inhibition of human CA46 cell growth in a cell viability assay.
|
Homo sapiens
|
293.39
nM
|
|
|
SANGER: Inhibition of human IM-9 cell growth in a cell viability assay.
|
Homo sapiens
|
346.91
nM
|
|
|
SANGER: Inhibition of human SK-MEL-3 cell growth in a cell viability assay.
|
Homo sapiens
|
105.1
nM
|
|
|
SANGER: Inhibition of human NKM-1 cell growth in a cell viability assay.
|
Homo sapiens
|
0.00709
nM
|
|
|
SANGER: Inhibition of human EGI-1 cell growth in a cell viability assay.
|
Homo sapiens
|
213.86
nM
|
|
|
SANGER: Inhibition of human no-11 cell growth in a cell viability assay.
|
Homo sapiens
|
736.68
nM
|
|
|
Cytotoxicity against human PANC1 cells by crystal violet staining
|
Homo sapiens
|
1.0
nM
|
|
|
Antiproliferative activity at human DMS53 cells after 72 hrs by MTT assay
|
Homo sapiens
|
9.0
nM
|
|
|
Cytotoxicity against human PANC1 cells after 48 hrs by WST-8 assay
|
Homo sapiens
|
110.0
nM
|
|
|
Cytotoxicity against human MRC5 cells after 48 hrs by SRB assay
|
Homo sapiens
|
6.3
nM
|
|
|
SANGER: Inhibition of human NCI-H2405 cell growth in a cell viability assay.
|
Homo sapiens
|
19.1
nM
|
|
|
Cytotoxicity against human paclitaxel resistant K562 cells after 3 days by MTT assay
|
Homo sapiens
|
6.0
nM
|
|
|
Antiproliferative activity against human K562 cells after 3 days by MTS assay
|
Homo sapiens
|
100.0
nM
|
|
|
SANGER: Inhibition of human NCI-H441 cell growth in a cell viability assay.
|
Homo sapiens
|
5.597
nM
|
|
|
Cytostatic activity against human CCRF-CEM cells after 3 days by MTS assay
|
Homo sapiens
|
20.0
nM
|
|
|
Cytotoxicity against human MCF7 cells incubated for 72 hrs under normoxic condition by MTT assay
|
Homo sapiens
|
570.0
nM
|
|
|
SANGER: Inhibition of human SUP-T1 cell growth in a cell viability assay.
|
Homo sapiens
|
23.47
nM
|
|
|
SANGER: Inhibition of human BL-70 cell growth in a cell viability assay.
|
Homo sapiens
|
110.97
nM
|
|
|
SANGER: Inhibition of human NCI-H1651 cell growth in a cell viability assay.
|
Homo sapiens
|
21.11
nM
|
|
|
In vitro cytotoxic activity against prostate carcinoma (DU-145) cells assayed by inhibition of [3H]-labeled thymidine incorporation
|
Homo sapiens
|
35.6
nM
|
|
|
Cytotoxicity against human Aspc-1 cells by crystal violet staining
|
Homo sapiens
|
4.0
nM
|
|
|
SANGER: Inhibition of human LS-513 cell growth in a cell viability assay.
|
Homo sapiens
|
887.61
nM
|
|
|
Cytotoxicity against human MRC5 cells treated at 2:1 and 5:1 alpha-lipoic acid to compound ratio after 48 hrs by SRB assay in presence of alpha-lipoic acid
|
Homo sapiens
|
3.9
nM
|
|
|
SANGER: Inhibition of human OVCAR-8 cell growth in a cell viability assay.
|
Homo sapiens
|
7.904
nM
|
|
|
Cytotoxicity against human CFPAC-1 cells assessed as reduction of cell survival after 96 hrs by MTT assay
|
Homo sapiens
|
350.0
nM
|
|
|
SANGER: Inhibition of human MC-IXC cell growth in a cell viability assay.
|
Homo sapiens
|
2.264
nM
|
|
|
SANGER: Inhibition of human IST-SL1 cell growth in a cell viability assay.
|
Homo sapiens
|
197.47
nM
|
|
|
SANGER: Inhibition of human NCI-H748 cell growth in a cell viability assay.
|
Homo sapiens
|
354.58
nM
|
|
|
SANGER: Inhibition of human 8305C cell growth in a cell viability assay.
|
Homo sapiens
|
9.64
nM
|
|
|
SANGER: Inhibition of human SBC-5 cell growth in a cell viability assay.
|
Homo sapiens
|
0.005701
nM
|
|
|
Antiproliferative activity against human A2780 cells expressing p53 after 72 hrs by celltiter-glo assay
|
Homo sapiens
|
35.0
nM
|
|
|
Antiviral activity against thymidine kinase positive Varicella zoster virus OKA infected in human HEL cells assessed as reduction in virus plaque formation measured on day 5 post-viral infection
|
Human alphaherpesvirus 3
|
28.0
nM
|
|
|
Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay
|
Homo sapiens
|
650.0
nM
|
|
|
SANGER: Inhibition of human KYSE-70 cell growth in a cell viability assay.
|
Homo sapiens
|
299.69
nM
|
|
|
SANGER: Inhibition of human NB1 cell growth in a cell viability assay.
|
Homo sapiens
|
487.53
nM
|
|
|
SANGER: Inhibition of human MZ7-mel cell growth in a cell viability assay.
|
Homo sapiens
|
42.66
nM
|
|
|
SANGER: Inhibition of human SIMA cell growth in a cell viability assay.
|
Homo sapiens
|
161.25
nM
|
|
|
SANGER: Inhibition of human NCI-H2122 cell growth in a cell viability assay.
|
Homo sapiens
|
0.09455
nM
|
|
|
SANGER: Inhibition of human BE-13 cell growth in a cell viability assay.
|
Homo sapiens
|
5.21
nM
|
|
|
SANGER: Inhibition of human HPAF-II cell growth in a cell viability assay.
|
Homo sapiens
|
428.47
nM
|
|
|
Antiproliferative activity against human PC-3 cells after 48 hrs by MTT assay
|
Homo sapiens
|
220.0
nM
|
|
|
Cytotoxicity against human CFPAC-1 cells incubated for 24 hrs by MTT assay
|
Homo sapiens
|
22.0
nM
|
|
|
SANGER: Inhibition of human CPC-N cell growth in a cell viability assay.
|
Homo sapiens
|
329.0
nM
|
|
|
SANGER: Inhibition of human HSC-3 cell growth in a cell viability assay.
|
Homo sapiens
|
1.905
nM
|
|
|
SANGER: Inhibition of human MFH-ino cell growth in a cell viability assay.
|
Homo sapiens
|
1.656
nM
|
|
|
SANGER: Inhibition of human MFE-296 cell growth in a cell viability assay.
|
Homo sapiens
|
51.35
nM
|
|
|
Cytotoxicity against human Patu-02 cells by crystal violet staining
|
Homo sapiens
|
3.4
nM
|
|
|
Cytostatic activity against human BxPC3 cells after 72 hrs by MTS assay
|
Homo sapiens
|
670.0
nM
|
|
|
Growth inhibition of SW1573 cells by SRB assay
|
Homo sapiens
|
16.0
nM
|
|
|
Cytotoxicity against human A549 cells treated at LA + compound sequent. LA for 24 hrs), LA + GEM (24 hrs additional, total 48 hrs) 2:1 alpha-lipoic acid to compound ratio after 48 hrs by SRB assay in presence of alpha-lipoic acid
|
Homo sapiens
|
29.0
nM
|
|
|
SANGER: Inhibition of human HH cell growth in a cell viability assay.
|
Homo sapiens
|
35.06
nM
|
|
|
SANGER: Inhibition of human EB2 cell growth in a cell viability assay.
|
Homo sapiens
|
2.012
nM
|
|
|
SANGER: Inhibition of human IST-MES1 cell growth in a cell viability assay.
|
Homo sapiens
|
773.54
nM
|
|
|
SANGER: Inhibition of human KYSE-510 cell growth in a cell viability assay.
|
Homo sapiens
|
0.000975
nM
|
|
|
SANGER: Inhibition of human RPMI-6666 cell growth in a cell viability assay.
|
Homo sapiens
|
0.06524
nM
|
|
|
Cytotoxicity against human MIA PaCa-2 cells expressing CD73 assessed as reduction in cell viability by CCK8 assay
|
Homo sapiens
|
230.0
nM
|
|
|
Cytotoxicity against human Jurkat cells assessed as reduction in cell viability after 72 hrs by MTS assay
|
Homo sapiens
|
23.0
nM
|
|
|
Cytostatic activity against human HeLa cells after 4 days by coulter counter analysis
|
Homo sapiens
|
9.9
nM
|
|
|
SANGER: Inhibition of human KM12 cell growth in a cell viability assay.
|
Homo sapiens
|
91.49
nM
|
|
|
SANGER: Inhibition of human CGTH-W-1 cell growth in a cell viability assay.
|
Homo sapiens
|
2.723
nM
|
|
|
SANGER: Inhibition of human NH-12 cell growth in a cell viability assay.
|
Homo sapiens
|
25.5
nM
|
|
|
Cytostatic activity against human K562-TAX cells after 3 days by MTS assay
|
Homo sapiens
|
50.0
nM
|
|
|
SANGER: Inhibition of human DBTRG-05MG cell growth in a cell viability assay.
|
Homo sapiens
|
121.82
nM
|
|
|
Growth inhibition of A549 cells by SRB assay in presence of dipyridamole
|
Homo sapiens
|
225.0
nM
|
|
|
SANGER: Inhibition of human COLO-668 cell growth in a cell viability assay.
|
Homo sapiens
|
2.66
nM
|
|
|
SANGER: Inhibition of human NCI-H510A cell growth in a cell viability assay.
|
Homo sapiens
|
33.27
nM
|
|
|
Antiproliferative activity against human U266 cells after 48 hrs by MTT assay
|
Homo sapiens
|
220.0
nM
|
|
|
Inhibitory activity against SK-LU-1 (human,lung,adenocarcinoma) cell line
|
Homo sapiens
|
55.0
nM
|
|
|
Cytotoxicity against p53 deficient human HCT116 cells assessed as cell growth inhibition after 72 hrs by MTS assay
|
Homo sapiens
|
410.0
nM
|
|
|
SANGER: Inhibition of human NCI-H596 cell growth in a cell viability assay.
|
Homo sapiens
|
225.13
nM
|
|
|
SANGER: Inhibition of human EHEB cell growth in a cell viability assay.
|
Homo sapiens
|
226.51
nM
|
|
|
SANGER: Inhibition of human LC-2-ad cell growth in a cell viability assay.
|
Homo sapiens
|
0.06528
nM
|
|
|
SANGER: Inhibition of human NCI-H727 cell growth in a cell viability assay.
|
Homo sapiens
|
2.506
nM
|
|
|
Cytotoxicity against human Bel7402 cells after 72 hrs by MTT assay
|
Homo sapiens
|
840.0
nM
|
|
|
SANGER: Inhibition of human HCE-T cell growth in a cell viability assay.
|
Homo sapiens
|
12.42
nM
|
|
|
SANGER: Inhibition of human 23132-87 cell growth in a cell viability assay.
|
Homo sapiens
|
43.05
nM
|
|
|
SANGER: Inhibition of human SNB75 cell growth in a cell viability assay.
|
Homo sapiens
|
37.24
nM
|
|
|
Cytotoxicity against human LNCAP cells after 3 days by MTT assay
|
Homo sapiens
|
512.0
nM
|
|
|
SANGER: Inhibition of human NY cell growth in a cell viability assay.
|
Homo sapiens
|
30.18
nM
|
|
|
SANGER: Inhibition of human ARH-77 cell growth in a cell viability assay.
|
Homo sapiens
|
0.07107
nM
|
|
|
Growth inhibition of human MIAPaCa2 cells after 48 hrs by MTT assay
|
Homo sapiens
|
30.0
%
|
|
|
SANGER: Inhibition of human HuCCT1 cell growth in a cell viability assay.
|
Homo sapiens
|
20.58
nM
|
|
|
SANGER: Inhibition of human ONS-76 cell growth in a cell viability assay.
|
Homo sapiens
|
8.677
nM
|
|
|
SANGER: Inhibition of human COLO-741 cell growth in a cell viability assay.
|
Homo sapiens
|
120.12
nM
|
|
|
Antiproliferative activity against human DU145 cells by MTT assay
|
Homo sapiens
|
3.5
nM
|
|
|
SANGER: Inhibition of human RH-1 cell growth in a cell viability assay.
|
Homo sapiens
|
0.007176
nM
|
|
|
SANGER: Inhibition of human CCF-STTG1 cell growth in a cell viability assay.
|
Homo sapiens
|
31.42
nM
|
|
|
Antiproliferative activity against human HCT15 cells expressing p53 after 72 hrs by celltiter-glo assay
|
Homo sapiens
|
10.0
nM
|
|
|
SANGER: Inhibition of human NCI-H1793 cell growth in a cell viability assay.
|
Homo sapiens
|
223.63
nM
|
|
|
SANGER: Inhibition of human MCF7 cell growth in a cell viability assay.
|
Homo sapiens
|
0.1359
nM
|
|
|
SANGER: Inhibition of human NCI-H64 cell growth in a cell viability assay.
|
Homo sapiens
|
150.93
nM
|
|
|
SANGER: Inhibition of human CMK cell growth in a cell viability assay.
|
Homo sapiens
|
0.05862
nM
|
|
|
SANGER: Inhibition of human SBC-1 cell growth in a cell viability assay.
|
Homo sapiens
|
165.57
nM
|
|
|
SANGER: Inhibition of human HLE cell growth in a cell viability assay.
|
Homo sapiens
|
3.004
nM
|
|
|
Antiproliferative activity against NHDF expressing p53 gene after 72 hrs by proliferative assay
|
Homo sapiens
|
22.1
nM
|
|
|
SANGER: Inhibition of human MDA-MB-361 cell growth in a cell viability assay.
|
Homo sapiens
|
460.64
nM
|
|
|
Cytotoxicity against human MIAPaCa2 cells after 24 hrs by MTT colorimetric assay
|
Homo sapiens
|
600.0
nM
|
|
|
SANGER: Inhibition of human NUGC-3 cell growth in a cell viability assay.
|
Homo sapiens
|
18.34
nM
|
|
|
Cytotoxicity against mouse L1210 cells after 3 days by MTT assay
|
Mus musculus
|
7.0
nM
|
|
|
SANGER: Inhibition of human NCI-H2347 cell growth in a cell viability assay.
|
Homo sapiens
|
792.01
nM
|
|
|
SANGER: Inhibition of human KYSE-150 cell growth in a cell viability assay.
|
Homo sapiens
|
8.469
nM
|
|
|
SANGER: Inhibition of human BHT-101 cell growth in a cell viability assay.
|
Homo sapiens
|
210.39
nM
|
|
|
SANGER: Inhibition of human HTC-C3 cell growth in a cell viability assay.
|
Homo sapiens
|
996.5
nM
|
|
|
SANGER: Inhibition of human NCI-H446 cell growth in a cell viability assay.
|
Homo sapiens
|
269.11
nM
|
|
|
SANGER: Inhibition of human NCI-H522 cell growth in a cell viability assay.
|
Homo sapiens
|
4.337
nM
|
|
|
SANGER: Inhibition of human SK-NEP-1 cell growth in a cell viability assay.
|
Homo sapiens
|
22.93
nM
|
|
|
Cytotoxicity against HUVEC assessed as cell after 48 hrs by MTT assay
|
Homo sapiens
|
3.0
nM
|
|
|
SANGER: Inhibition of human CCRF-CEM cell growth in a cell viability assay.
|
Homo sapiens
|
18.85
nM
|
|
|
SANGER: Inhibition of human SR cell growth in a cell viability assay.
|
Homo sapiens
|
2.121
nM
|
|
|
SANGER: Inhibition of human KS-1 cell growth in a cell viability assay.
|
Homo sapiens
|
166.52
nM
|
|
|
SANGER: Inhibition of human SU-DHL-1 cell growth in a cell viability assay.
|
Homo sapiens
|
62.66
nM
|
|
|
SANGER: Inhibition of human HCC1599 cell growth in a cell viability assay.
|
Homo sapiens
|
70.22
nM
|
|
|
SANGER: Inhibition of human CAMA-1 cell growth in a cell viability assay.
|
Homo sapiens
|
395.8
nM
|
|
|
SANGER: Inhibition of human SK-N-DZ cell growth in a cell viability assay.
|
Homo sapiens
|
86.56
nM
|
|
|
SANGER: Inhibition of human A388 cell growth in a cell viability assay.
|
Homo sapiens
|
1.365
nM
|
|
|
SANGER: Inhibition of human SIG-M5 cell growth in a cell viability assay.
|
Homo sapiens
|
0.01042
nM
|
|
|
Antiproliferative activity against human HCT116-E6 cells expressing p53 after 72 hrs by celltiter-glo assay
|
Homo sapiens
|
500.0
nM
|
|
|
Cytotoxicity against human Patu-S cells by crystal violet staining
|
Homo sapiens
|
3.2
nM
|
|
|
SANGER: Inhibition of human SW48 cell growth in a cell viability assay.
|
Homo sapiens
|
462.59
nM
|
|
|
Antiproliferative activity against p53 deficient human SW480 cells after 72 hrs by proliferative assay
|
Homo sapiens
|
13.6
nM
|
|
|
Antiproliferative activity against human U2OS cells expressing p53 gene after 72 hrs by proliferative assay
|
Homo sapiens
|
90.7
nM
|
|
|
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging
|
Chlorocebus sabaeus
|
0.22
%
|
|
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging
|
Chlorocebus sabaeus
|
0.22
%
|
|
|
Anticancer activity against human SMMC-7721 cells assessed as inhibition of cell proliferation at 1 uM measured after 72 hrs by MTT assay
|
Homo sapiens
|
38.5
%
|
|
|
Antiproliferative activity against human PDAC-3 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay
|
Homo sapiens
|
5.54
nM
|
|
|
SANGER: Inhibition of human KYSE-180 cell growth in a cell viability assay.
|
Homo sapiens
|
12.81
nM
|
|
|
Cytotoxicity against mouse P388D1 cells after 3 days by MTT assay
|
Mus musculus
|
19.0
nM
|
|
|
SANGER: Inhibition of human RT-112 cell growth in a cell viability assay.
|
Homo sapiens
|
0.1273
nM
|
|
|
SANGER: Inhibition of human RPMI-8226 cell growth in a cell viability assay.
|
Homo sapiens
|
16.02
nM
|
|
|
SANGER: Inhibition of human OMC-1 cell growth in a cell viability assay.
|
Homo sapiens
|
583.33
nM
|
|
|
SANGER: Inhibition of human SN12C cell growth in a cell viability assay.
|
Homo sapiens
|
497.34
nM
|
|
|
SANGER: Inhibition of human A427 cell growth in a cell viability assay.
|
Homo sapiens
|
323.98
nM
|
|
|
Inhibitory activity against HT-29 (human,colon,adenocarcinoma) cell line
|
Homo sapiens
|
43.0
nM
|
|
|
SANGER: Inhibition of human SW13 cell growth in a cell viability assay.
|
Homo sapiens
|
330.37
nM
|
|
|
Antitumor activity against human MIAPaCa2 cells xenografted in SCID mouse assessed as reduction in tumor volume at 70 mg/kg, ip twice a week
|
Homo sapiens
|
56.2
%
|
|
|
Cytotoxicity against human MRC5 cells treated at LA + compound sequent. LA for 24 hrs), LA + GEM (24 hrs additional, total 48 hrs) 2:1 alpha-lipoic acid to compound ratio after 48 hrs by SRB assay in presence of alpha-lipoic acid
|
Homo sapiens
|
21.6
nM
|
|
|
SANGER: Inhibition of human SCC-25 cell growth in a cell viability assay.
|
Homo sapiens
|
289.28
nM
|
|
|
SANGER: Inhibition of human HOP-62 cell growth in a cell viability assay.
|
Homo sapiens
|
222.58
nM
|
|
|
Antiproliferative activity against human HCT15 cells expressing p53 gene after 72 hrs by proliferative assay
|
Homo sapiens
|
9.9
nM
|
|
|
Cytotoxicity against human U2OS cells assessed as cell growth inhibition after 72 hrs by MTS assay
|
Homo sapiens
|
180.0
nM
|
|
|
Cytotoxicity against human Colo-357 cells by crystal violet staining
|
Homo sapiens
|
0.36
nM
|
|
|
SANGER: Inhibition of human ML-2 cell growth in a cell viability assay.
|
Homo sapiens
|
25.74
nM
|
|
|
SANGER: Inhibition of human LOUCY cell growth in a cell viability assay.
|
Homo sapiens
|
20.66
nM
|
|
|
SANGER: Inhibition of human EFO-27 cell growth in a cell viability assay.
|
Homo sapiens
|
9.046
nM
|
|
|
Growth inhibition of SW1573 cells by SRB assay in presence of dipyridamole
|
Homo sapiens
|
275.0
nM
|
|
|
Cytotoxicity against human MDA-MB-231 cells after 3 days by MTT assay
|
Homo sapiens
|
245.0
nM
|
|
|
SANGER: Inhibition of human ES1 cell growth in a cell viability assay.
|
Homo sapiens
|
0.02682
nM
|
|
|
SANGER: Inhibition of human SW872 cell growth in a cell viability assay.
|
Homo sapiens
|
0.7647
nM
|
|
|
SANGER: Inhibition of human TUR cell growth in a cell viability assay.
|
Homo sapiens
|
32.03
nM
|
|
|
SANGER: Inhibition of human GCT cell growth in a cell viability assay.
|
Homo sapiens
|
405.1
nM
|
|
|
SANGER: Inhibition of human TE-6 cell growth in a cell viability assay.
|
Homo sapiens
|
250.35
nM
|
|
|
SANGER: Inhibition of human 8-MG-BA cell growth in a cell viability assay.
|
Homo sapiens
|
5.93
nM
|
|
|
Antiproliferative activity against p53 deficient human HCT116/E6 cells after 72 hrs by proliferative assay
|
Homo sapiens
|
896.5
nM
|
|
|
SANGER: Inhibition of human A704 cell growth in a cell viability assay.
|
Homo sapiens
|
53.78
nM
|
|
|
Antiproliferative activity against human HCT116 cells expressing p53 gene after 72 hrs by proliferative assay
|
Homo sapiens
|
9.7
nM
|
|
|
SANGER: Inhibition of human SW1573 cell growth in a cell viability assay.
|
Homo sapiens
|
457.33
nM
|
|
|
SANGER: Inhibition of human IGROV-1 cell growth in a cell viability assay.
|
Homo sapiens
|
0.145
nM
|
|
|
SANGER: Inhibition of human NOS-1 cell growth in a cell viability assay.
|
Homo sapiens
|
32.44
nM
|
|
|
SANGER: Inhibition of human HMV-II cell growth in a cell viability assay.
|
Homo sapiens
|
24.34
nM
|
|
|
Antiviral activity against HIV-1 infected in HEK293T cells assessed as inhibition of viral replication treated with compound 2 hrs prior to viral infection and measured after 24 hrs by flow cytometry
|
Human immunodeficiency virus 1
|
16.3
nM
|
|
|
SANGER: Inhibition of human SNU-423 cell growth in a cell viability assay.
|
Homo sapiens
|
62.48
nM
|
|
|
SANGER: Inhibition of human MHH-NB-11 cell growth in a cell viability assay.
|
Homo sapiens
|
385.97
nM
|
|
|
Cytostatic activity against human HCT116 cells after 3 days by MTS assay
|
Homo sapiens
|
30.0
nM
|
|
|
SANGER: Inhibition of human NCI-H1770 cell growth in a cell viability assay.
|
Homo sapiens
|
55.04
nM
|
|
|
SANGER: Inhibition of human A2780 cell growth in a cell viability assay.
|
Homo sapiens
|
0.2702
nM
|
|
|
SANGER: Inhibition of human U-87-MG cell growth in a cell viability assay.
|
Homo sapiens
|
190.57
nM
|
|
|
Cytotoxicity against human K562 cells assessed as cell growth inhibition after 72 hrs by MTS assay
|
Homo sapiens
|
100.0
nM
|
|
|
SANGER: Inhibition of human ACN cell growth in a cell viability assay.
|
Homo sapiens
|
0.2436
nM
|
|
|
Antiproliferative activity against p53 deficient human SF268 cells after 72 hrs
|
Homo sapiens
|
10.3
nM
|
|
|
SANGER: Inhibition of human DU-4475 cell growth in a cell viability assay.
|
Homo sapiens
|
3.143
nM
|
|
|
SANGER: Inhibition of human MEL-HO cell growth in a cell viability assay.
|
Homo sapiens
|
5.162
nM
|
|
|
SANGER: Inhibition of human NCI-N87 cell growth in a cell viability assay.
|
Homo sapiens
|
333.04
nM
|
|
|
SANGER: Inhibition of human MS-1 cell growth in a cell viability assay.
|
Homo sapiens
|
46.34
nM
|
|
|
Cytotoxicity against human BxPC3 cells after 5 days by PrestoBlue assay
|
Homo sapiens
|
10.0
nM
|
|
|
SANGER: Inhibition of human NCI-H810 cell growth in a cell viability assay.
|
Homo sapiens
|
8.558
nM
|
|
|
SANGER: Inhibition of human COLO-679 cell growth in a cell viability assay.
|
Homo sapiens
|
10.07
nM
|
|
|
SANGER: Inhibition of human ALL-PO cell growth in a cell viability assay.
|
Homo sapiens
|
0.008298
nM
|
|
|
SANGER: Inhibition of human MV-4-11 cell growth in a cell viability assay.
|
Homo sapiens
|
0.0004578
nM
|
|
|
Cytotoxicity against mouse CT26 cells after 3 days by MTT assay
|
Mus musculus
|
6.0
nM
|
|
|
SANGER: Inhibition of human Calu-6 cell growth in a cell viability assay.
|
Homo sapiens
|
1.735
nM
|
|
|
SANGER: Inhibition of human SW1990 cell growth in a cell viability assay.
|
Homo sapiens
|
113.07
nM
|
|
|
SANGER: Inhibition of human A172 cell growth in a cell viability assay.
|
Homo sapiens
|
24.71
nM
|
|
|
SANGER: Inhibition of human PF-382 cell growth in a cell viability assay.
|
Homo sapiens
|
44.22
nM
|
|
|
SANGER: Inhibition of human HC-1 cell growth in a cell viability assay.
|
Homo sapiens
|
0.3273
nM
|
|
|
Cytotoxicity against human Patu-T cells by crystal violet staining
|
Homo sapiens
|
2.8
nM
|
|
|
SANGER: Inhibition of human CAS-1 cell growth in a cell viability assay.
|
Homo sapiens
|
955.08
nM
|
|
|
SANGER: Inhibition of human BC-3 cell growth in a cell viability assay.
|
Homo sapiens
|
220.65
nM
|
|
|
SANGER: Inhibition of human UACC-257 cell growth in a cell viability assay.
|
Homo sapiens
|
364.12
nM
|
|
|
SANGER: Inhibition of human ETK-1 cell growth in a cell viability assay.
|
Homo sapiens
|
8.076
nM
|
|
|
Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay
|
Homo sapiens
|
1.4
nM
|
|
|
SANGER: Inhibition of human A101D cell growth in a cell viability assay.
|
Homo sapiens
|
9.373
nM
|
|
|
SANGER: Inhibition of human HT-1376 cell growth in a cell viability assay.
|
Homo sapiens
|
368.95
nM
|
|
|
Cytotoxicity against human K562-TAX cells assessed as cell growth inhibition after 72 hrs by MTS assay
|
Homo sapiens
|
50.0
nM
|
|
|
Antimigratory activity against human PANC1 cells measured after 18 hrs in presence of mitomycin C using crystal violet staining by inverted microscopy-based transwell assay
|
Homo sapiens
|
160.0
nM
|
|
|
Antiproliferative activity against human U2OS cells after 3 days by MTS assay
|
Homo sapiens
|
180.0
nM
|
|
|
SANGER: Inhibition of human Calu-1 cell growth in a cell viability assay.
|
Homo sapiens
|
220.03
nM
|
|
|
SANGER: Inhibition of human KU812 cell growth in a cell viability assay.
|
Homo sapiens
|
1.913
nM
|
|
|
Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay
|
Homo sapiens
|
36.4
nM
|
|
|
Cytotoxicity against human HCT116 cells assessed as cell growth inhibition after 72 hrs by MTS assay
|
Homo sapiens
|
30.0
nM
|
|
|
SANGER: Inhibition of human SK-LU-1 cell growth in a cell viability assay.
|
Homo sapiens
|
0.6552
nM
|
|
|
SANGER: Inhibition of human GB-1 cell growth in a cell viability assay.
|
Homo sapiens
|
5.845
nM
|
|
|
Growth inhibition of A2780 cells by SRB assay in presence of dipyridamole
|
Homo sapiens
|
15.0
nM
|
|
|
SANGER: Inhibition of human LB831-BLC cell growth in a cell viability assay.
|
Homo sapiens
|
41.85
nM
|
|
|
Growth inhibition of human MDA-MB-231 cells after 72 hrs by Hoechst 33258 dye based fluorescence assay
|
Homo sapiens
|
30.0
nM
|
|
|
Cytotoxicity against human RT112 cells assessed as cell viability by MTT assay in absence of dCK substrate deoxycytidine
|
Homo sapiens
|
1.4
nM
|
|
|
Antiproliferative activity against human HEL cells after 48 hrs by MTT assay
|
Homo sapiens
|
480.0
nM
|
|
|
SANGER: Inhibition of human PC-14 cell growth in a cell viability assay.
|
Homo sapiens
|
203.31
nM
|
|
|
Antiproliferative activity against human DU-145 cells measured after 72 hrs by MTT assay
|
Homo sapiens
|
399.0
nM
|
|
|
Antiproliferative activity against human ES2 cells after 48 hrs by MTT assay
|
Homo sapiens
|
530.0
nM
|
|
|
SANGER: Inhibition of human GAMG cell growth in a cell viability assay.
|
Homo sapiens
|
3.739
nM
|
|
|
Cytotoxicity against human MIAPaCa2 cells assessed as decrease in cell proliferation after 72 hrs by MTT assay
|
Homo sapiens
|
110.0
nM
|
|
|
Cytotoxicity against human K562 cells assessed as reduction of cell survival after 48 hrs by MTT assay
|
Homo sapiens
|
50.0
nM
|
|
|
SANGER: Inhibition of human BxPC-3 cell growth in a cell viability assay.
|
Homo sapiens
|
36.91
nM
|
|
|
SANGER: Inhibition of human NCI-H2087 cell growth in a cell viability assay.
|
Homo sapiens
|
2.143
nM
|
|
|
SANGER: Inhibition of human NCI-H226 cell growth in a cell viability assay.
|
Homo sapiens
|
316.96
nM
|
|
|
SANGER: Inhibition of human THP-1 cell growth in a cell viability assay.
|
Homo sapiens
|
664.2
nM
|
|
|
Antiproliferative activity against human p53 deficient SF268 cells after 72 hrs by celltiter-glo assay
|
Homo sapiens
|
10.0
nM
|
|
|
SANGER: Inhibition of human NCI-H1299 cell growth in a cell viability assay.
|
Homo sapiens
|
0.1566
nM
|
|
|
SANGER: Inhibition of human 22RV1 cell growth in a cell viability assay.
|
Homo sapiens
|
96.48
nM
|
|
|
Cytotoxicity against human T24 cells treated at 2:1 and 5:1 alpha-lipoic acid to compound ratio after 48 hrs by SRB assay in presence of alpha-lipoic acid
|
Homo sapiens
|
3.9
nM
|
|
|
SANGER: Inhibition of human MG-63 cell growth in a cell viability assay.
|
Homo sapiens
|
1.335
nM
|
|
|
SANGER: Inhibition of human JEG-3 cell growth in a cell viability assay.
|
Homo sapiens
|
276.69
nM
|
|
|
Growth inhibition of CEM cells by SRB assay
|
Homo sapiens
|
130.0
nM
|
|
|
SANGER: Inhibition of human KP-4 cell growth in a cell viability assay.
|
Homo sapiens
|
5.611
nM
|
|
|
SANGER: Inhibition of human NCI-H1304 cell growth in a cell viability assay.
|
Homo sapiens
|
384.54
nM
|
|
|
Antiproliferative activity against human MCF7 cells measured after 72 hrs by MTT assay
|
Homo sapiens
|
38.0
nM
|
|
|
SANGER: Inhibition of human NOMO-1 cell growth in a cell viability assay.
|
Homo sapiens
|
28.68
nM
|
|
|
Cytotoxicity against human BV173 cells after 3 days by MTT assay
|
Homo sapiens
|
1.0
nM
|
|
|
SANGER: Inhibition of human HD-MY-Z cell growth in a cell viability assay.
|
Homo sapiens
|
6.679
nM
|
|
|
Cytotoxicity against human NCI-H460 cells after 48 hrs by WST-8 assay
|
Homo sapiens
|
230.0
nM
|
|
|
SANGER: Inhibition of human TE-10 cell growth in a cell viability assay.
|
Homo sapiens
|
16.21
nM
|
|
|
SANGER: Inhibition of human OS-RC-2 cell growth in a cell viability assay.
|
Homo sapiens
|
6.681
nM
|
|
|
SANGER: Inhibition of human Caov-3 cell growth in a cell viability assay.
|
Homo sapiens
|
54.13
nM
|
|
|
SANGER: Inhibition of human LXF-289 cell growth in a cell viability assay.
|
Homo sapiens
|
3.314
nM
|
|
|
Antiproliferative activity against human MCF7 cells expressing p53 gene after 72 hrs by proliferative assay
|
Homo sapiens
|
80.3
nM
|
|
|
SANGER: Inhibition of human HGC-27 cell growth in a cell viability assay.
|
Homo sapiens
|
9.601
nM
|
|
|
SANGER: Inhibition of human Ca9-22 cell growth in a cell viability assay.
|
Homo sapiens
|
1.538
nM
|
|
|
SANGER: Inhibition of human OVCAR-5 cell growth in a cell viability assay.
|
Homo sapiens
|
305.77
nM
|
|
|
SANGER: Inhibition of human NCI-H526 cell growth in a cell viability assay.
|
Homo sapiens
|
109.88
nM
|
|
|
SANGER: Inhibition of human A204 cell growth in a cell viability assay.
|
Homo sapiens
|
11.16
nM
|
|
|
Growth inhibition of human BxPC3 cells after 96 hrs by SRB assay
|
Homo sapiens
|
6.0
nM
|
|
|
SANGER: Inhibition of human C3A cell growth in a cell viability assay.
|
Homo sapiens
|
8.839
nM
|
|
|
SANGER: Inhibition of human G-361 cell growth in a cell viability assay.
|
Homo sapiens
|
21.07
nM
|
|
|
Antiproliferative activity against human A549 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay
|
Homo sapiens
|
18.8
nM
|
|
|
SANGER: Inhibition of human Detroit562 cell growth in a cell viability assay.
|
Homo sapiens
|
10.42
nM
|
|
|
Inhibitory activity against CEM-SS (human T-4 lymphoblastoid clone) cell line
|
Homo sapiens
|
30.0
nM
|
|
|
SANGER: Inhibition of human U251 cell growth in a cell viability assay.
|
Homo sapiens
|
22.27
nM
|
|
|
SANGER: Inhibition of human BC-1 cell growth in a cell viability assay.
|
Homo sapiens
|
33.77
nM
|
|
|
SANGER: Inhibition of human NCI-H1734 cell growth in a cell viability assay.
|
Homo sapiens
|
11.29
nM
|
|
|
SANGER: Inhibition of human BB30-HNC cell growth in a cell viability assay.
|
Homo sapiens
|
0.2312
nM
|
|
|
SANGER: Inhibition of human RCM-1 cell growth in a cell viability assay.
|
Homo sapiens
|
664.78
nM
|
|
|
SANGER: Inhibition of human J-RT3-T3-5 cell growth in a cell viability assay.
|
Homo sapiens
|
67.18
nM
|
|
|
SANGER: Inhibition of human REH cell growth in a cell viability assay.
|
Homo sapiens
|
14.51
nM
|
|
|
SANGER: Inhibition of human KNS-42 cell growth in a cell viability assay.
|
Homo sapiens
|
735.82
nM
|
|
|
SANGER: Inhibition of human BB65-RCC cell growth in a cell viability assay.
|
Homo sapiens
|
0.05119
nM
|
|
|
SANGER: Inhibition of human EM-2 cell growth in a cell viability assay.
|
Homo sapiens
|
159.9
nM
|
|
|
SANGER: Inhibition of human PANC-10-05 cell growth in a cell viability assay.
|
Homo sapiens
|
15.38
nM
|
|
|
SANGER: Inhibition of human KLE cell growth in a cell viability assay.
|
Homo sapiens
|
459.42
nM
|
|
|
SANGER: Inhibition of human SK-MM-2 cell growth in a cell viability assay.
|
Homo sapiens
|
479.12
nM
|
|
|
SANGER: Inhibition of human NCI-H661 cell growth in a cell viability assay.
|
Homo sapiens
|
104.02
nM
|
|
|
SANGER: Inhibition of human SF295 cell growth in a cell viability assay.
|
Homo sapiens
|
51.12
nM
|
|
|
Antiproliferative activity against human U937 cells after 48 hrs by MTT assay
|
Homo sapiens
|
70.0
nM
|
|
|
SANGER: Inhibition of human NCI-H1650 cell growth in a cell viability assay.
|
Homo sapiens
|
25.4
nM
|
|
|
SANGER: Inhibition of human SKG-IIIa cell growth in a cell viability assay.
|
Homo sapiens
|
809.72
nM
|
|
|
Cytostatic activity against human CEM cells after 3 days by coulter counter analysis
|
Homo sapiens
|
69.0
nM
|
|
|
Growth inhibition of human HCT116 cells after 72 hrs by Hoechst 33258 dye based fluorescence assay
|
Homo sapiens
|
30.0
nM
|
|
|
SANGER: Inhibition of human KYSE-520 cell growth in a cell viability assay.
|
Homo sapiens
|
92.84
nM
|
|
|
SANGER: Inhibition of human HOP-92 cell growth in a cell viability assay.
|
Homo sapiens
|
950.75
nM
|
|
|
SANGER: Inhibition of human MEG-01 cell growth in a cell viability assay.
|
Homo sapiens
|
1.266
nM
|
|
|
SANGER: Inhibition of human EoL-1-cell cell growth in a cell viability assay.
|
Homo sapiens
|
0.6162
nM
|
|
|
SANGER: Inhibition of human RS4-11 cell growth in a cell viability assay.
|
Homo sapiens
|
0.4326
nM
|
|
|
Cytotoxicity against human MES-SA cells after 3 days by MTT assay
|
Homo sapiens
|
5.0
nM
|
|
|
SANGER: Inhibition of human HuH-7 cell growth in a cell viability assay.
|
Homo sapiens
|
568.61
nM
|
|
|
Antiviral activity against Zika virus infected in human RPE cells assessed as inhibition of virus-induced cytopathic effect measured at 48 hrs post-viral infection by CellTiter Glo assay
|
Zika virus
|
10.0
nM
|
|
|
SANGER: Inhibition of human HAL-01 cell growth in a cell viability assay.
|
Homo sapiens
|
8.195
nM
|
|
|
Cytotoxicity against human BT549 cells after 3 days by MTT assay
|
Homo sapiens
|
8.0
nM
|
|
|
Antiviral activity against Human rhinovirus 1B infected in human HeLa cells assessed as inhibition of virus-induced cytopathicity measured after 2 days by SRB method
|
Human rhinovirus 1B
|
810.0
nM
|
|
|
SANGER: Inhibition of human RCC10RGB cell growth in a cell viability assay.
|
Homo sapiens
|
633.74
nM
|
|
|
SANGER: Inhibition of human L-363 cell growth in a cell viability assay.
|
Homo sapiens
|
95.5
nM
|
|
|
SANGER: Inhibition of human SCC-3 cell growth in a cell viability assay.
|
Homo sapiens
|
89.64
nM
|
|
|
Antiproliferative activity at human A549 cells after 72 hrs by MTT assay
|
Homo sapiens
|
20.0
nM
|
|
|
Antiproliferative activity against p53 gene knocked out human HCT116 cells after 3 days by MTS assay
|
Homo sapiens
|
410.0
nM
|
|
|
SANGER: Inhibition of human A673 cell growth in a cell viability assay.
|
Homo sapiens
|
34.17
nM
|
|
|
Antiproliferative activity against human KG1 cells after 48 hrs by MTT assay
|
Homo sapiens
|
860.0
nM
|
|
|
SANGER: Inhibition of human HOS cell growth in a cell viability assay.
|
Homo sapiens
|
0.04803
nM
|
|
|
SANGER: Inhibition of human NCI-H2081 cell growth in a cell viability assay.
|
Homo sapiens
|
310.77
nM
|
|
|
SANGER: Inhibition of human MZ1-PC cell growth in a cell viability assay.
|
Homo sapiens
|
254.35
nM
|
|
|
SANGER: Inhibition of human FTC-133 cell growth in a cell viability assay.
|
Homo sapiens
|
87.49
nM
|
|
|
SANGER: Inhibition of human COR-L279 cell growth in a cell viability assay.
|
Homo sapiens
|
53.91
nM
|
|
|
SANGER: Inhibition of human NCI-H1355 cell growth in a cell viability assay.
|
Homo sapiens
|
0.3806
nM
|
|
|
SANGER: Inhibition of human CAL-148 cell growth in a cell viability assay.
|
Homo sapiens
|
17.23
nM
|
|
|
SANGER: Inhibition of human RPMI-2650 cell growth in a cell viability assay.
|
Homo sapiens
|
17.59
nM
|
|
|
Inhibitory activity against U373-MG (human, glioblastoma) cell line
|
Homo sapiens
|
130.0
nM
|
|
|
Cytotoxicity against human T24 cells after 48 hrs by SRB assay
|
Homo sapiens
|
6.9
nM
|
|
|
SANGER: Inhibition of human HN cell growth in a cell viability assay.
|
Homo sapiens
|
54.09
nM
|
|
|
SANGER: Inhibition of human A431 cell growth in a cell viability assay.
|
Homo sapiens
|
0.1831
nM
|
|
|
SANGER: Inhibition of human CTB-1 cell growth in a cell viability assay.
|
Homo sapiens
|
53.39
nM
|
|
|
SANGER: Inhibition of human ES6 cell growth in a cell viability assay.
|
Homo sapiens
|
0.5856
nM
|
|
|
SANGER: Inhibition of human LB2241-RCC cell growth in a cell viability assay.
|
Homo sapiens
|
0.03179
nM
|
|
|
SANGER: Inhibition of human SF268 cell growth in a cell viability assay.
|
Homo sapiens
|
0.9274
nM
|
|
|
SANGER: Inhibition of human SW962 cell growth in a cell viability assay.
|
Homo sapiens
|
52.41
nM
|
|
|
Cytotoxicity against human PC3 cells assessed as reduction in cell viability after 72 hrs by MTS assay
|
Homo sapiens
|
65.0
nM
|
|
|
SANGER: Inhibition of human LB1047-RCC cell growth in a cell viability assay.
|
Homo sapiens
|
0.2688
nM
|
|
|
SANGER: Inhibition of human BHY cell growth in a cell viability assay.
|
Homo sapiens
|
1.141
nM
|
|
|
SANGER: Inhibition of human SJRH30 cell growth in a cell viability assay.
|
Homo sapiens
|
106.41
nM
|
|
|
SANGER: Inhibition of human 769-P cell growth in a cell viability assay.
|
Homo sapiens
|
0.1231
nM
|
|
|
Antiproliferative activity against p53 deficient human COLO205 cells after 72 hrs
|
Homo sapiens
|
51.4
nM
|
|
|
SANGER: Inhibition of human NCI-H1618 cell growth in a cell viability assay.
|
Homo sapiens
|
197.56
nM
|
|
|
SANGER: Inhibition of human GDM-1 cell growth in a cell viability assay.
|
Homo sapiens
|
62.54
nM
|
|
|
Cytotoxicity against human MCF7 cells after 72 hrs by resazurin assay
|
Homo sapiens
|
60.0
nM
|
|
|
SANGER: Inhibition of human MEL-JUSO cell growth in a cell viability assay.
|
Homo sapiens
|
0.03908
nM
|
|
|
SANGER: Inhibition of human JiyoyeP-2003 cell growth in a cell viability assay.
|
Homo sapiens
|
39.38
nM
|
|
|
SANGER: Inhibition of human TK10 cell growth in a cell viability assay.
|
Homo sapiens
|
14.49
nM
|
|
|
SANGER: Inhibition of human NCI-H1882 cell growth in a cell viability assay.
|
Homo sapiens
|
82.45
nM
|
|
|
SANGER: Inhibition of human DMS-273 cell growth in a cell viability assay.
|
Homo sapiens
|
3.07
nM
|
|
|
SANGER: Inhibition of human BEN cell growth in a cell viability assay.
|
Homo sapiens
|
237.91
nM
|
|
|
SANGER: Inhibition of human KYSE-410 cell growth in a cell viability assay.
|
Homo sapiens
|
55.87
nM
|
|
|
SANGER: Inhibition of human HSC-2 cell growth in a cell viability assay.
|
Homo sapiens
|
3.03
nM
|
|
|
Antiviral activity against Polio virus Mahoney infected in human HeLa cells assessed as inhibition of viral replication incubated for 2 days by luminescence analysis
|
Enterovirus C
|
300.0
nM
|
|
|
SANGER: Inhibition of human HSC-4 cell growth in a cell viability assay.
|
Homo sapiens
|
0.1022
nM
|
|
|
Antiproliferative activity against human MCF7 cells expressing p53 after 72 hrs by celltiter-glo assay
|
Homo sapiens
|
80.0
nM
|
|
|
In vitro cytotoxic activity against nonsmall cell lung carcinoma (NCI-H460) cells assayed by inhibition of [3H]-labeled thymidine incorporation
|
Homo sapiens
|
7.8
nM
|
|
|
Antiproliferative activity against human Capan-1 cells assessed as reduction in cell growth incubated for 72 hrs by SRB assay
|
Homo sapiens
|
20.0
nM
|
|
|
SANGER: Inhibition of human KP-N-YS cell growth in a cell viability assay.
|
Homo sapiens
|
14.97
nM
|
|
|
SANGER: Inhibition of human NCI-H460 cell growth in a cell viability assay.
|
Homo sapiens
|
13.54
nM
|
|
|
SANGER: Inhibition of human MONO-MAC-6 cell growth in a cell viability assay.
|
Homo sapiens
|
24.84
nM
|
|
|
SANGER: Inhibition of human BV-173 cell growth in a cell viability assay.
|
Homo sapiens
|
17.27
nM
|
|
|
Cytotoxicity against daunorubicin resistant human CCRF-CEM cells assessed as cell growth inhibition after 72 hrs by MTS assay
|
Homo sapiens
|
20.0
nM
|
|
|
SANGER: Inhibition of human IST-MEL1 cell growth in a cell viability assay.
|
Homo sapiens
|
0.07259
nM
|
|
|
Inhibitory activity against HL-60 (human, promyelocytic leukemia) cell line
|
Homo sapiens
|
330.0
nM
|
|
|
SANGER: Inhibition of human HCC2998 cell growth in a cell viability assay.
|
Homo sapiens
|
6.339
nM
|
|
|
SANGER: Inhibition of human WSU-NHL cell growth in a cell viability assay.
|
Homo sapiens
|
50.35
nM
|
|
|
SANGER: Inhibition of human CTV-1 cell growth in a cell viability assay.
|
Homo sapiens
|
14.14
nM
|
|
|
SANGER: Inhibition of human NCI-H1792 cell growth in a cell viability assay.
|
Homo sapiens
|
259.04
nM
|
|
|
SANGER: Inhibition of human SK-MEL-30 cell growth in a cell viability assay.
|
Homo sapiens
|
0.5545
nM
|
|
|
SANGER: Inhibition of human LB2518-MEL cell growth in a cell viability assay.
|
Homo sapiens
|
64.52
nM
|
|
|
SANGER: Inhibition of human IMR-5 cell growth in a cell viability assay.
|
Homo sapiens
|
82.96
nM
|
|
|
Antiproliferative activity against human SUIT-2 cells assessed as reduction in cell growth incubated for 72 hrs by SRB assay
|
Homo sapiens
|
10.0
nM
|
|
|
SANGER: Inhibition of human COLO-680N cell growth in a cell viability assay.
|
Homo sapiens
|
75.49
nM
|
|
|
Growth inhibition of H292 cells by SRB assay
|
Homo sapiens
|
13.0
nM
|
|
|
SANGER: Inhibition of human NCI-H1437 cell growth in a cell viability assay.
|
Homo sapiens
|
9.418
nM
|
|
|
SANGER: Inhibition of human LU-134-A cell growth in a cell viability assay.
|
Homo sapiens
|
40.02
nM
|
|
|
SANGER: Inhibition of human BT-20 cell growth in a cell viability assay.
|
Homo sapiens
|
181.74
nM
|
|
|
SANGER: Inhibition of human C8166 cell growth in a cell viability assay.
|
Homo sapiens
|
13.08
nM
|
|
|
Antiproliferative activity against NHDF expressing p53 after 72 hrs by celltiter-glo assay
|
Homo sapiens
|
20.0
nM
|
|
|
SANGER: Inhibition of human NCI-H1694 cell growth in a cell viability assay.
|
Homo sapiens
|
61.29
nM
|
|
|
SANGER: Inhibition of human RPMI-8402 cell growth in a cell viability assay.
|
Homo sapiens
|
45.93
nM
|
|
|
Cytotoxicity against human A2780 cells after 72 hrs by MTT assay
|
Homo sapiens
|
310.0
nM
|
|
|
SANGER: Inhibition of human U-266 cell growth in a cell viability assay.
|
Homo sapiens
|
607.94
nM
|
|
|
SANGER: Inhibition of human OCI-AML2 cell growth in a cell viability assay.
|
Homo sapiens
|
0.1466
nM
|
|
|
SANGER: Inhibition of human MKN45 cell growth in a cell viability assay.
|
Homo sapiens
|
17.73
nM
|
|
|
SANGER: Inhibition of human KG-1 cell growth in a cell viability assay.
|
Homo sapiens
|
62.2
nM
|
|
|
Cytotoxicity against human MCF7 cells after 3 days by MTT assay
|
Homo sapiens
|
149.0
nM
|
|
|
Inhibitory activity against BG-1 (human, breast adenocarcinoma) cell line
|
Homo sapiens
|
680.0
nM
|
|
|
SANGER: Inhibition of human SNG-M cell growth in a cell viability assay.
|
Homo sapiens
|
0.04247
nM
|
|
|
SANGER: Inhibition of human HO-1-N-1 cell growth in a cell viability assay.
|
Homo sapiens
|
23.77
nM
|
|
|
Antiproliferative activity against human KG-1 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
|
Homo sapiens
|
1.8
nM
|
|
|
SANGER: Inhibition of human HT-144 cell growth in a cell viability assay.
|
Homo sapiens
|
4.92
nM
|
|
|
SANGER: Inhibition of human HCC1806 cell growth in a cell viability assay.
|
Homo sapiens
|
2.908
nM
|
|
|
SANGER: Inhibition of human ATN-1 cell growth in a cell viability assay.
|
Homo sapiens
|
0.8069
nM
|
|
|
SANGER: Inhibition of human UACC-62 cell growth in a cell viability assay.
|
Homo sapiens
|
812.6
nM
|
|
|
Cytotoxicity against human HeLa cells assessed as reduction of cell survival after 96 hrs by MTT assay
|
Homo sapiens
|
900.0
nM
|
|
|
Growth inhibition of H292 cells by SRB assay in presence of dipyridamole
|
Homo sapiens
|
210.0
nM
|
|
|
SANGER: Inhibition of human BFTC-905 cell growth in a cell viability assay.
|
Homo sapiens
|
0.00515
nM
|
|
|
Cytotoxicity against human Calu1 cells after 48 hrs by WST-8 assay
|
Homo sapiens
|
520.0
nM
|
|
|
Growth inhibition of human MDA-MB-231 cells at 0.1 uM after 96 hrs by sulforhodamine B assay relative to control
|
Homo sapiens
|
1.0
%
|
|
|
SANGER: Inhibition of human Daoy cell growth in a cell viability assay.
|
Homo sapiens
|
0.4565
nM
|
|
|
SANGER: Inhibition of human HT-3 cell growth in a cell viability assay.
|
Homo sapiens
|
200.54
nM
|
|
|
SANGER: Inhibition of human NCI-H82 cell growth in a cell viability assay.
|
Homo sapiens
|
372.97
nM
|
|
|
SANGER: Inhibition of human MIA-PaCa-2 cell growth in a cell viability assay.
|
Homo sapiens
|
23.36
nM
|
|
|
SANGER: Inhibition of human A3-KAW cell growth in a cell viability assay.
|
Homo sapiens
|
0.5512
nM
|
|
|
SANGER: Inhibition of human CAL-33 cell growth in a cell viability assay.
|
Homo sapiens
|
1.893
nM
|
|
|
Antiproliferative activity against human Panc-1 cells assessed as reduction in cell growth incubated for 72 hrs by SRB assay
|
Homo sapiens
|
150.0
nM
|
|
|
SANGER: Inhibition of human SK-PN-DW cell growth in a cell viability assay.
|
Homo sapiens
|
0.2656
nM
|
|
|
SANGER: Inhibition of human AM-38 cell growth in a cell viability assay.
|
Homo sapiens
|
0.1215
nM
|
|
|
SANGER: Inhibition of human MPP-89 cell growth in a cell viability assay.
|
Homo sapiens
|
692.28
nM
|
|
|
Antiinvasive activity against human PANC1 cells measured after 18 hrs in presence of mitomycin C using crystal violet staining by inverted microscopy-based matrigel coated transwell assay
|
Homo sapiens
|
160.0
nM
|
|
|
SANGER: Inhibition of human MES-SA cell growth in a cell viability assay.
|
Homo sapiens
|
0.9049
nM
|
|
|
Antiproliferative activity against p53 deficient human K562 cells after 72 hrs
|
Homo sapiens
|
745.9
nM
|
|
|
SANGER: Inhibition of human NCI-H747 cell growth in a cell viability assay.
|
Homo sapiens
|
42.28
nM
|
|
|
SANGER: Inhibition of human Calu-3 cell growth in a cell viability assay.
|
Homo sapiens
|
17.29
nM
|
|
|
SANGER: Inhibition of human CAL-120 cell growth in a cell viability assay.
|
Homo sapiens
|
575.88
nM
|
|
|
SANGER: Inhibition of human CAL-27 cell growth in a cell viability assay.
|
Homo sapiens
|
35.16
nM
|
|
|
SANGER: Inhibition of human NCI-H2228 cell growth in a cell viability assay.
|
Homo sapiens
|
0.314
nM
|
|
|
SANGER: Inhibition of human P30-OHK cell growth in a cell viability assay.
|
Homo sapiens
|
1.459
nM
|
|
|
SANGER: Inhibition of human MOLT-4 cell growth in a cell viability assay.
|
Homo sapiens
|
65.28
nM
|
|
|
SANGER: Inhibition of human NCI-H2141 cell growth in a cell viability assay.
|
Homo sapiens
|
644.04
nM
|
|
|
SANGER: Inhibition of human KARPAS-422 cell growth in a cell viability assay.
|
Homo sapiens
|
85.79
nM
|
|
|
SANGER: Inhibition of human ChaGo-K-1 cell growth in a cell viability assay.
|
Homo sapiens
|
695.6
nM
|
|
|
Cytotoxicity against human DAN-G cells by crystal violet staining
|
Homo sapiens
|
3.4
nM
|
|
|
SANGER: Inhibition of human LS-123 cell growth in a cell viability assay.
|
Homo sapiens
|
40.28
nM
|
|
|
SANGER: Inhibition of human K052 cell growth in a cell viability assay.
|
Homo sapiens
|
136.71
nM
|
|
|
SANGER: Inhibition of human NB12 cell growth in a cell viability assay.
|
Homo sapiens
|
155.15
nM
|
|
|
SANGER: Inhibition of human NCI-SNU-1 cell growth in a cell viability assay.
|
Homo sapiens
|
0.01596
nM
|
|
|
SANGER: Inhibition of human K-562 cell growth in a cell viability assay.
|
Homo sapiens
|
332.98
nM
|
|
|
SANGER: Inhibition of human SF539 cell growth in a cell viability assay.
|
Homo sapiens
|
1.023
nM
|
|
|
SANGER: Inhibition of human GR-ST cell growth in a cell viability assay.
|
Homo sapiens
|
0.05953
nM
|
|
|
Cytotoxicity against human CFPAC-1 cells assessed as reduction of cell survival after 72 hrs by MTT assay
|
Homo sapiens
|
470.0
nM
|
|
|
SANGER: Inhibition of human LS-411N cell growth in a cell viability assay.
|
Homo sapiens
|
29.88
nM
|
|
|
Antiviral activity against Human cytomegalovirus AD169 infected in human HEL cells assessed as reduction in virus plaque formation measured on day 6 to 7 post-viral infection
|
Human herpesvirus 5
|
74.0
nM
|
|
|
Cytostatic activity against human CEM/DNR cells after 3 days by MTS assay
|
Homo sapiens
|
100.0
nM
|
|
|
SANGER: Inhibition of human SW620 cell growth in a cell viability assay.
|
Homo sapiens
|
1.346
nM
|
|
|
Cytotoxicity against human T3M4 cells by crystal violet staining
|
Homo sapiens
|
1.5
nM
|
|
|
SANGER: Inhibition of human RKO cell growth in a cell viability assay.
|
Homo sapiens
|
0.02785
nM
|
|
|
SANGER: Inhibition of human T98G cell growth in a cell viability assay.
|
Homo sapiens
|
539.48
nM
|
|
|
SANGER: Inhibition of human ABC-1 cell growth in a cell viability assay.
|
Homo sapiens
|
22.65
nM
|
|
|
SANGER: Inhibition of human GCIY cell growth in a cell viability assay.
|
Homo sapiens
|
92.69
nM
|
|
|
SANGER: Inhibition of human NMC-G1 cell growth in a cell viability assay.
|
Homo sapiens
|
8.762
nM
|
|
|
Cytotoxicity against human Ramos cells assessed as reduction in cell viability after 72 hrs by MTS assay
|
Homo sapiens
|
0.03
nM
|
|
|
Cytotoxicity against human PANC1 cells after 72 hrs under normoxic condition by MTT assay
|
Homo sapiens
|
400.0
nM
|
|
|
SANGER: Inhibition of human PANC-03-27 cell growth in a cell viability assay.
|
Homo sapiens
|
3.513
nM
|
|
|
SANGER: Inhibition of human MHH-PREB-1 cell growth in a cell viability assay.
|
Homo sapiens
|
248.04
nM
|
|
|
Antiviral activity against thymidine kinase deficient Varicella zoster virus 07-1 infected in human HEL cells assessed as reduction in virus plaque formation measured on day 5 post-viral infection
|
Human alphaherpesvirus 3
|
54.0
nM
|
|
|
SANGER: Inhibition of human NB69 cell growth in a cell viability assay.
|
Homo sapiens
|
1.046
nM
|
|
|
SANGER: Inhibition of human HCC38 cell growth in a cell viability assay.
|
Homo sapiens
|
21.95
nM
|
|
|
SANGER: Inhibition of human VMRC-RCZ cell growth in a cell viability assay.
|
Homo sapiens
|
1.542
nM
|
|
|
Antiproliferative activity against human BxPC3 cells assessed as reduction in cell growth at 10 to 100 uM incubated for 72 hrs by MTS assay relative to control
|
Homo sapiens
|
30.0
%
|
|
|
SANGER: Inhibition of human M14 cell growth in a cell viability assay.
|
Homo sapiens
|
514.66
nM
|
|
|
SANGER: Inhibition of human LU-65 cell growth in a cell viability assay.
|
Homo sapiens
|
303.81
nM
|
|
|
SANGER: Inhibition of human NCI-H2342 cell growth in a cell viability assay.
|
Homo sapiens
|
7.634
nM
|
|
|
SANGER: Inhibition of human NCI-H1703 cell growth in a cell viability assay.
|
Homo sapiens
|
31.78
nM
|
|
|
SANGER: Inhibition of human ESS-1 cell growth in a cell viability assay.
|
Homo sapiens
|
0.02858
nM
|
|
|
SANGER: Inhibition of human HL-60 cell growth in a cell viability assay.
|
Homo sapiens
|
15.69
nM
|
|
|
Antiproliferative activity against p53 deficient human OVCAR8 cells after 72 hrs by proliferative assay
|
Homo sapiens
|
2.6
nM
|
|
|
SANGER: Inhibition of human EW-18 cell growth in a cell viability assay.
|
Homo sapiens
|
72.75
nM
|
|
|
SANGER: Inhibition of human GI-1 cell growth in a cell viability assay.
|
Homo sapiens
|
2.764
nM
|
|
|
SANGER: Inhibition of human NCI-H650 cell growth in a cell viability assay.
|
Homo sapiens
|
565.69
nM
|
|
|
SANGER: Inhibition of human NCI-H69 cell growth in a cell viability assay.
|
Homo sapiens
|
459.48
nM
|
|
|
SANGER: Inhibition of human NCI-H1623 cell growth in a cell viability assay.
|
Homo sapiens
|
187.08
nM
|
|
|
Cytotoxicity against human HCT116 cells by sulforhodamine B method
|
Homo sapiens
|
5.0
nM
|
|
|
Antiproliferative activity against human U2OS cells expressing p53 after 72 hrs by celltiter-glo assay
|
Homo sapiens
|
180.0
nM
|
|
|
SANGER: Inhibition of human KGN cell growth in a cell viability assay.
|
Homo sapiens
|
0.01081
nM
|
|
|
SANGER: Inhibition of human H4 cell growth in a cell viability assay.
|
Homo sapiens
|
2.175
nM
|
|
|
SANGER: Inhibition of human 697 cell growth in a cell viability assay.
|
Homo sapiens
|
6.247
nM
|
|
|
Cytotoxicity against mouse EL4 cells after 3 days by MTT assay
|
Mus musculus
|
7.0
nM
|
|
|
SANGER: Inhibition of human NB10 cell growth in a cell viability assay.
|
Homo sapiens
|
24.37
nM
|
|
